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1 Introduction 
 
1.1 eEF2K 
 
Eukaryotic elongation factor 2 kinase (eEF2K) is a ubiquitous, well conserved protein involved in 
the control of protein translation, whose catalytic activity is Ca
2+
-dependent and is therefore also 
known as Ca
2+
/Calmodulin-dependent kinase III (CaMKIII). Upon activation, eEF2K 
phosphorylates and inhibits eukaryotic elongation factor 2 (eEF2), its only known substrate. This 
leads to a halt of protein synthesis at the level of elongation (Ryazanov et al., 1988; Diggle et al., 
1999; Pavur et al., 2000; Browne and Proud, 2002; Ryazanov, 2002; Pigott et al., 2012).  
 
1.1.1 Structure of eEF2K 
 
In terms of sequence similarity, eEF2K is not related to the superfamilies of conventional protein 
kinases but instead belongs to a heterogenous small group of kinases called α-kinases, which have a 
high degree of similarity in their catalytic region. However, the three-dimensional structure of α-
kinases and the sequence of their functionally relevant motifs may be very similar to that of 
conventional protein kinases, indicating that they may serve similar functions in the cell and 
probably have a mutual evolutionary origin (Pavur et al., 2000; Drennan and Ryazanov, 2004). 
eEF2K is a middle sized protein (length: 725 aa for human eEF2K) which is well-conserved 
between mammals (Ryazanov et al., 1997). It consists of an N-terminal catalytic domain which 
includes the adenosine triphosphate (ATP)-binding site, a C-terminal domain that is necessary for 
eEF2 binding, and an interposed unorganized linker region. Even further N-terminally there is the 
Calmodulin (CaM) binding region (Ryazanov et al., 1997; Diggle et al., 1999; Pavur et al., 2000). 
Several upstream kinases such as AMP-activated protein kinase (AMPK), P70S6 kinase (p70S6K), 
and p90 ribosomal S6 kinase (p90RSK1) phosphorylate and regulate eEF2K by acting on the linker 
region, (see paragraph 1.1.2) (Pigott et al., 2012). 
eEF2K point-mutated at Ser366 renders eEF2K constituitively active. This mutated  version of 
eEF2K is described in literature and is known as “eEF2Kca” (eEF2K constituitively active) 
(Verpelli et al., 2010). Instead, there are also several described versions of eEF2K with point 
mutations which render the kinase catalytically inactive, one example of which is “K170M” (point 
mutation at position 170; substitution of Lys with Met) (Pigott et al., 2012). Both of these constructs 
were extensively used in the course of this study (see results section 3.1 and onwards). 
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Figure 1: Basic structure of human eEF2K and point mutations of the eEF2Kca and K170M constructs. eEF2K is a well-conserved Ca2+/CaM-
dependent kinase (also known as Ca2+/CaM-dependent kinase III) (Ryazanov et al., 1997) and is a middle sized protein (length: 725 aa for human 
eEF2K). It consists of an N-terminal catalytic domain (aa 123-335; in turquoise) where the ATP-binding site resides and an even further N-terminally 
located CaM binding region (aa 51-96; in green). A mutation in the catalytic domain at Lys170 renders eEF2K catalytically inactive and leads to a 
version of eEF2K called “K170M” (indicated by arrow). C-terminally, there is a domain that is necessary for eEF2 binding (eEF2-targeting domain; 
aa 521-725; in yellow). More precisely, only the very C-terminal tip of eEF2K (aa 706-725) is necessary for eEF2 binding (Diggle et al., 1999). 
Lastly, there is an interposed unorganized linker region (aa 336-520; in red) which is the target of several upstream regulating kinases such as AMPK, 
p70S6K, and p90RSK1 (see paragraph 1.1.2) (Pigott et al., 2012). A mutation in the linker region at Ser366 renders eEF2K constituitively active and 
leads to a version of eEF2K called “eEF2Kca” (indicated by arrow). 
 
1.1.2 Regulation of eEF2K 
 
Since eEF2K downregulates translation at the elongation level, it is well positioned as an element to 
be regulated by various basic cellular events since protein synthesis is an ATP-dependent process 
which must therefore be tightly controlled by any organism. Even though most researchers agree 
that protein translation is mainly regulated at the initiation level (Browne and Proud, 2002; 
Sonenberg and Hinnebusch, 2009; Gildish et al., 2012), it has been shown eEF2K is strongly 
influenced by upstream cellular events and associated kinases which execute the control of eEF2K 
activity (Browne and Proud, 2002) (Fig. 2). 
eEF2K activity is increased by both low pH and low energy (i.e. a low availability of aa) in the 
mammalian cell (low energy in cells leads to activation of AMPK, which in turn activates eEF2K 
by phosphorylating it on Ser398). This has been explained by the fact that under tissue acidosis 
(which may take place under conditions like hypoxia and ischemia) or under conditions where 
energy is sparse, protein translation must be inhibited to conserve energy in order to react properly 
to these forms of cell stress (Dorovkov et al., 2002; Browne et al., 2004). Also, eEF2K activity is 
increased by elevated levels of the second messenger Ca
2+
 and the Ca
2+
-dependent protein CaM
 
(Nairn et al., 1985; Mitsui et al., 1993; Dorovkov et al., 2002) which represents a rather unspecific 
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way of changing eEF2K activity since Ca
2+
 is a very broadly employed signalling element 
(Clapham, 2007; Chuderland and Seger, 2008; Fortin et al., 2013). However, there are also 
examples of changes in intracellular Ca
2+
 in response to specific signalling pathways which 
subsequently change eEF2K activity. For example, in the context of neuronal cells, Ca
2+
 influx after 
N-methyl-D-aspartate receptor (NMDAR) activation appears to be strongly related to eEF2K 
activation and subsequent neuronal events which depend on the regulation of protein translation 
(Scheetz et al., 1997, 2000; Nosyreva et al., 2013) (see paragraph 1.3). Interestingly, Ca
2+
/CaM is 
also necessary for autophosphorylation of eEF2K, which tends to activate eEF2K further (e.g. 
autophosphorylation on Thr348) and appears to render eEF2K activity independent of Ca
2+
/CaM 
(Pyr Dit Ruys et al., 2012; Tavares et al., 2012). Lastly, it has also been shown that eEF2K activity 
can be increased by the activation of metabotropic glutamate receptors (mGluRs), possibly since 
mGluR activation liberates eEF2K from its inhibiting interaction with the receptor itself (Park et al., 
2008) (see paragraph 1.3). 
On the contrary, eEF2 activity is reduced by mammalian target of rapamycin (mTOR) signalling 
which triggers p70S6K-dependent phosphorylation of eEF2K on Ser366, a major phosphorylation 
site that is associated with inhibition of eEF2K (Wang et al., 2001). Since mTor activity is increased 
by insulin and the availability of aa or energy in the cell (Browne and Proud, 2002), it may play the 
biological counterpart to eEF2K activation by AMPK which serves to activate protein translation 
when the circumstances allow for cell growth and other ATP-dependent processes in the cell that 
depend on protein synthesis. Another well-described signalling cascade that inactivates eEF2K is 
mitogen-activated protein/extracellular signal-regulated kinase (MEK/ERK) signalling which leads 
to eEF2K phosphorylation on Ser366 by employing p90
RSK1
 as a mediator (Wang et al., 2001; 
Browne and Proud, 2002). 
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Figure 2: Regulation of eEF2K activity by upstream events have an effect on protein translation. Activation is indicated by blue arrows, inhibition 
is indicated by red T-bars. Since eEF2K activity leads to a downregulation of peptide chain elongation, it is a good target of signalling events enabling 
proper cellular responses to stimuli which demand changes in protein translation. Notably, changes in cellular pH and availability of aa have a strong 
influence on eEF2K activity. E.g. when there are few aa, AMPK is activated which subsequently activates eEF2K, thereby reducing protein 
translation which is a sensible response to few aa since the available energy in the cell is probably sparse and protein translation must therefore be 
reduced to a minimum. Conversely, an abundance of aa activates mTOR signalling which, in turn, inactivates eEF2K. Moreover, eEF2K activity is 
dynamically altered by specific signalling events, such as NMDAR-mediated influx of Ca2+ into neurons or MEK/ERK signalling. Interestingly, 
eEF2K activity is also increased by Ca2+/CaM-dependent autophosphorylation which, in turn, renders eEF2K activity independent of Ca2+/CaM. 
 
1.1.3 eEF2K/eEF2 pathway 
 
As mentioned, eEF2K downregulates protein synthesis, since its activity leads to a phosphorylation 
of eEF2 on Thr56 (henceforth referred to as peEF2 or phosphorylated eEF2). More specifically, 
peEF2 is not able to bind to the ribosomes and can therefore not catalyze the peptidyl-Transfer 
RNA (tRNA) translocation from the acceptor region to the peptidyl region, effectively rendering 
eEF2 catalytically inactive and halting peptide chain elongation/protein translation at the elongation 
level (Diggle et al., 1999; Pigott et al., 2012). Importantly, there are also phosphatases acting on 
peEF2, reconverting it into eEF2, thereby restoring peptide chain elongation. One of these 
phosphatases is protein phosphatase 2A (Browne and Proud, 2002; Hong-Brown et al., 2007; Kaul 
et al., 2011). The regulation of eEF2 activity and peptide chain elongation is therefore controlled by 
an array of phosphatases and a single kinase (namely eEF2K) since eEF2 is the only known 
substrate of eEF2K and increases in eEF2 phosphorylation have only been convincingly linked to 
eEF2K (Browne and Proud, 2002; Dorovkov et al., 2002; Ryazanov, 2002; Nosyreva et al., 2013).  
It is important to emphasize that the eEF2K/eEF2 pathway exists in every mammalian cell and is 
highly conserved (Kaul et al., 2011). It has been linked to cellular processes as diverse as cancer, 
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cytokine production, milk lactation, and synaptic processes in neurons (Chen et al., 2011; Kaul et 
al., 2011; Gonzalez-Teran et al., 2012; Leprivier et al., 2013; Taha et al., 2013). In this context it 
seems rather surprising that eEF2K-knockout (eEF2K-KO) mice do not show any obvious 
phenotypes since they are fertile, viabile, and do not show any behavioural abnormalities under 
physiological conditions (Ryazanov, 2002; Nosyreva et al., 2013). 
 
1.2 Synapses 
 
Synapses are highly specialized cell junctions where transduction of electrical signals takes place 
between neural cells- typically between two neurons, though the participitation of glial cells in 
synaptic processes has become increasingly obvious over the past years (Perea et al., 2009). The 
exchange of these electrical signals (of this “information”) can be viewed as a “communication” 
between neural cells that in vivo serves information processing which is crucial for an organism to 
respond adequately to changes in the surrounding and within the organism itself (Haydon, 2000; 
Breedlove et al., 2007). Based on the nature of signal transduction and the biochemical buildup, one 
can differentiate between two types of synapses- namely chemical and electrical ones. Chemical 
synapses are far more abundant than electrical ones and represent a much more complex subcellular 
compartment where the signal transduction can be heavily modified. Importantly, chemical 
synapses convey the electrical signals indirectly via biochemical agents (known as 
neurotransmitters) whereas electrical synapses convey the electrical signal directly via channels 
(known as gap junctions). As a result, signal transduction occurs faster at electrical synapses but is 
much less modifiable and therefore is not so versatilely employable for information processing in 
neural networks. For the present study, the relevant synapse is the chemical one so all of the 
following information refers to this type of synapse. 
 
1.2.1 Signal transduction at the chemical synapse: pre- and postsynapse 
 
In the classical view, the chemical synapse consists of a pre- and postsynaptic compartment, 
devided by an extracellular space called the synaptic cleft. Each compartment pertains to an 
individual neuron, one which (from an information processing persepective) is upstream of the 
synapse (called presynaptic neuron, contributes the presynaptic compartment) and one which is 
downstream (called postsynaptic neuron, contributes the postsynaptic compartment). 
When an action potential is generated at the axon hillock (compartment of neuronal soma with high 
concentration of voltage gated ion channels) of the presynaptic neuron, it is actively propogated 
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along the axon by voltage gated Na
+
 and K
+
 channels. It then induces the influx of Ca
2+
 via voltage-
dependent Ca
2+
 channels at the presynaptic compartment of the synapse. This, subsequently, 
triggers Ca
2+
-dependent events that eventually lead to the fusion of synaptic vesicles (SVs), which 
contain the neurotransmitters, with the cell membrane. After fusion of the SVs with the cell 
membrane, the neurotransmitters diffuse across the synaptic cleft and bind to receptors present at 
the cell surface of the postsynaptic compartment. For ionotropic receptors, this binding causes the 
receptor to allow for the entry of ions into the postsynaptic neuron which changes the probability 
for the generation of an axon potential at the axon hillock of this cell. Instead, activation of 
metabotropic receptors by neurotransmitters leads to a variety of cellular events one which is the 
induction of indirect entry of ions into the postsynaptic cell via the activation of second messengers 
(Kandel et al., 2000; Breedlove et al., 2007). 
The presynaptic compartment is highly organized to allow for the fusion of SVs and the release of 
neurotransmitters in response to Ca
2+
 influx and presents a complex protein machinery to do so 
(Frank et al., 2010). SVs consist of a lipid membrane with interspersed proteins that can enable 
Ca
2+
-dependent responses for the release of neurotransmitters into the synaptic cleft. Among other 
things, SVs must be trafficked to the presynapse, loaded with neurotransmitters, and docked at the 
site of release before fusion with the cell membrane. After the fusion with the cell membrane, SVs 
must then be endocytosed to allow for the refilling with neurotransmitters and so another cycle of 
neurotransmitter delivery via SVs (“SV cycle”) can begin (Sudhof, 2004). Some of the proteins 
involved in this SV cycle/ in SV dynamics are Glutamate decarboxylase-65 (GAD65), vesicular 
glutamate transporter (VGLUT), vesicular gamma-Aminobutyric acid (GABA) transporter 
(VGAT), Synapsin (Syn), Synaptotagmin (SYT), Synaptophysin (Syp) and Cask. For example, 
GAD65 is involved in the (local) synaptic synthesis of GABA, whereas VGLUT and VGAT are 
involved in the loading of SVs. Instead, Syns are involved in the anchoring of SVs to the 
presynaptic scaffold, as well as the Ca
2+
-dependent release of SVs from the scaffold, Syp appears to 
be relevant for the endocytosis of SVs, and adaptor proteins like Cask are indirectly involved in the 
anchoring SVs at the presynaptic release site (Kanaani et al., 2002; Tabuchi et al., 2002; Kwon and 
Chapman, 2011; Sudhof and Rizo, 2011). 
Instead, the postsynaptic compartment is highly organized to enable a response to neurotransmitter 
binding which includes (but is not limited to) a neurotransmitter-dependent influx of ions and a 
neurotransmitter-dependent induction of signalling cascades. For example, the postsynapse harbors 
neurotransmitter receptors like the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
(AMPAR), an ionotropic GluR, or the GABAA receptor (GABAAR) which represents the main 
ionotropic GABA receptor (GABAR). These ionotropic GluRs and GABARs are probably 
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heterotetra- and heteropentamers, respectively, consisting of such subunits as GluR1 (subunit 1 of 
the AMPAR) and GABAARα1 (α1 subunit of the GABAAR) (Dingledine et al., 1999; Sarto et al., 
2002). The postsynapse also harbors metabotropic neurotransmitter receptors like mGluRs or 
GABAB receptors which diversify the response of the postsynapse to neurotransmitters. 
Additionally, the postsynapse exhibits an extensive scaffold which links neurotransmitters with the 
cytoscelleton and signalling machinery; some prominent members of this scaffold include 
Postsynaptic Density protein 95 (PSD95) or Homer1. There are also cell adhesion molecules like 
neuroligin-1 (NLGN1), which are linked to presynaptically located cell adhesion molecules like 
neurexins and, finally, the postsynaptic compartment also exhibits many proteins which are related 
to synaptic and synapto-nuclear signalling like Ca
2+
/Calmodulin-dependent kinase II (CaMKII), 
neuronal nitric oxide synthases, or cyclic adenosine monophosphate response element-binding 
protein 2 (Sala et al., 2001; Iida et al., 2004; Arancibia-Carcamo and Moss, 2006; Fainzilber et al., 
2011; Sheng and Kim, 2011; Luo et al., 2012). 
Lastly, it is also noteworthy that the functionality of the chemical synapse does not only depend on 
the pre- and postsynaptic neuron but instead is also determined by astrocytes and other glia cells 
(Perea et al., 2009). Glia cells, which ensheath neurons and synapse, do not only function in 
stabilizing neurons and serving their metabolic processes but instead take an active role in 
signalling at the synapse despite their inability to generate action potentials. For example, astrocytes 
have been shown to change their activity in response to synaptically released neurotransmitters and 
can communicate between each other using Ca
2+
 as a second messenge. Conversely, changes in 
astrocyte activity can have an effect on neuronal activity. One striking example of this is that 
astrocytes have been shown to release D-serine in dependency of neuronal activity which, in turn, 
influences postsynaptic GluR-activation since D-serine is a co-agonist for the GluR called NMDAR 
(Panatier et al., 2006; Perea et al., 2009). 
 
1.2.2 Chemical Synapse: Excitatory and inhibitory synapse 
 
One can differentiate three classes of chemical synapses: excitatory synapses, inhibitory synapses, 
and complex/modulatory synapses. These synapses differ in biochemical buildup and in the 
neurotransmitters that are principally used. In the brain, excitatory synapses usually employ 
glutamate, inhibitory synapses usually employ GABA, and modulatory synapses can use a variety 
of neurotransmitters, such as melatonion, serotonin or dopamine.  
Simplified, activation of the excitatory synapse causes the release of glutamate from the presynaptic 
compartment and, in turn, leads to the activation of ionotropic GluRs which allow for the flux of 
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Na
+
, K
+
, and sometimes Ca
2+
. Due to the ionic concentrations of the extracellular and intracellular 
space, this causes a net influx of Na
+
 and outflux of K
+ 
which depolarizes the postsynaptic neuron 
and thereby increases the probability of the generation of an action potential at its axon hillock. 
With other words, activating excitatory synapses leads to the generation of an excitatory 
postsynaptic current (EPSC). Instead, activation of the inhibitory synapse causes the release of 
GABA from the presynaptic compartment and, subsequently, leads to the activation of ionotropic 
GABARs which allow for the flux of Cl
-
. Due to the ionic concentrations of the extracellular and 
intracellular space, this causes an influx of Cl
-
 which hyperpolarizes the postsynaptic neuron and 
thereby decreases the probability of the generation of an action potential at its axon hillock. With 
other words, activating inhibitory synapses leads to the generation of an inhibitory postsynaptic 
current (IPSC) (Junge, 1981). Activation of complex/modulatory synapses can lead to either an 
EPSC or IPSC at the postsynaptic neuron but is not of relevance in the context of this study. It is 
important to note that postsynaptic currents (PSCs) are not solely induced when the presynaptic 
compartment is activated as a consequence of presynaptically generated action potentials. Instead, 
PSCs can also be the consequence of spontaneous fusion of individual SVs which occurs largely 
independently of action potentials (Fatt and Katz, 1952). Since these spontaneous events lead to 
much smaller PSCs than those evoked by presynaptically generated action potentials, they are 
called miniature postsynaptic currents (mPSCs). mPSCs can occur at excitatory synapses where 
they cause miniature excitatory postsynaptic currents (mEPSCs) or they can occur at inhibitory 
synapses where they cause miniature inhibitory postsynaptic currents (mIPSCs). Importantly, 
mPSCs contain important information about the amount of functional synapses and can give an 
indication of the efficacy and dynamics of the pre- and postsynaptic compartment (see also 
paragraph 3.1.5). 
Morphologically, one can differentiate excitatory and inhibitory synapses by electron microscopy 
because the latter has a symmetric structure whereas the former has an asymmteric structure with a 
prominent postsynaptic structure called the postsynaptic density (the part of the postsynapse that is 
in near vicinity to the synaptic cleft is enriched in proteins and is therefore electron-dense). 
Additionally, the excitatory synapse usually exhibits (postsynaptic) dendritic protrusions called 
“spines”, whereas inhibitory synapses are positioned on the dendritic shaft [dendrites represent “the 
branched projections of a neuron that receive synaptic inputs conveyed by axons from other 
neurons” (Sheng and Kim, 2011)]. In addition, various structural and biochemical differences exist 
between excitatory and inhibitory synpapses. For example, excitatory synapses employ scaffolding 
proteins like PSD95 or Synapse-associated protein (SAP) 97 which contain PDZ domains to enable 
the (indirect) interaction with other scaffolding proteins like those of the ProSAP/Shank family 
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(Sheng and Kim, 2011). Instead, the scaffold of the inhibitory synapse employs proteins like 
Gephyrin or Profilin (Giesemann et al., 2003). 
  
1.3 eEF2K/eEF2 pathway and the chemical synapse 
 
Even though eEF2K and eEF2 are ubiquitously expressed and eEF2 phosphorylation is generally 
associated with reduced protein translation, it is likely that the eEF2K/eEF2 pathway regulates 
protein translation in a particular manner in neurons and possibly also in other cells. For example, it 
has been found that even though eEF2 phosphorylation is related with a decrease in general protein 
translation at synapses, it is actually associated with an increased expression of certain proteins in 
the vicinity of the synapse, though the mechanism by which this happens is poorly understood 
(Scheetz et al., 1997, 2000). This indicates that the eEF2K/eEF2 pathway can regulate protein 
translation not only in a cell-type specific manner but also in a fashion that is specific for 
subcellular compartments. In the context of neuroscience, particular attention has been paid to 
eEF2K and the eEF2K/eEF2 pathway not least because the activity of eEF2K is Ca
2+
-dependent and 
many synaptic processes involve Ca
2+
 (Breedlove et al., 2007; Sutton et al., 2007), which may 
suggest a link between these processes and eEF2K activity.  
In fact, there is a multitude of publications showing that certain synaptic functions involving GluRs 
like synaptic signal-transduction and synaptic plasticity (change of synaptic structure/strength in 
response to changes in synaptic activity) depend on eEF2K activity and vice versa (Taha et al., 
2013). For example, Davidkova and Carroll demonstrated that mGluR activation causes an eEF2K-
dependent upregulation of Microtubule-associated protein 1B (MAP1b) which, in turn, leads to the  
endocytosis of AMPARs. Our own group has shown that prolonged mGluR-mediated activation of 
eEF2K can increase the expression of Brain-derived neurotrophic factor (BDNF), which is essential 
for the proper morphology of dendritic spines (Verpelli et al., 2010). Interestingly, it has also been 
shown that a certain form of synaptic plasticity called mGluR-dependent-Long Term Depression 
(mGluR-LTD) depends on eEF2K activity as this form of synaptic plasticity is absent in eEF2K-
KO mice (Park et al., 2008). mGluR-LTD involves the reduction of synaptic strength in response to 
mGluR activation. This reduction in synaptic strenght can be the result of different cellular events, 
for example the endocytosis of GluRs (Citri and Malenka, 2008). Park et al. show that mGluR-
activation detaches eEF2K from the receptor itself which liberates eEF2K activity. eEF2K then 
phosphorylates eEF2 which for not well-understood reasons leads to the upregulation of activity-
regulated cytoskeletal-associated protein (Arc). Arc then leads to the endocytosis AMPARs, thereby 
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completing the process of mGluR-LTD since a reduction in surface AMPARs drastically decreases 
synaptic strength. 
Importantly, since eEF2K is a Ca
2+
-dependent kinase, a significant amount of research on eEF2K at 
the synapse has focused on the NMDAR, which can allow for the entry of Ca
2+
 into neurons 
(Dingledine et al., 1999). For example, brief activation of NMDARs triggers synaptic eEF2 
phosphorylation which leads to a local downregulation of general protein synthesis but curiously 
leads to an upregulation of the α subunit of CaMKII (“local” in this context means at or in the 
vicinity of the synapse) (Scheetz et al., 1997, 2000). Interestingly, several studies have also linked 
mEPSCs with eEF2K. Sutton et al. were the first to show that synaptic eEF2K activity and the 
associated decrease in general protein translation is increased in response to NMDAR-mediated 
Ca
2+
-influx triggered by mEPSCs. On the contrary, action potentials appear to reduce eEF2K 
activity, leading to an increase of protein translation. This result suggests that the eEF2K/eEF2 
pathway could represent a postsynaptic decoder of spontaneous (mPSC-mediated) and evoked 
(action potential-mediated) neurotransmission. In line with this result, other groups have found that 
blocking the mEPSC-triggered NMDAR activation with the NMDAR antagonist ketamin decreases 
eEF2K activity. This, in turn, leads to the upregulation of BDNF and AMPARs, which appears to 
be the molecular basis for the rapid antidepressive effect of ketamin (Autry et al., 2011; Nosyreva et 
al., 2013). The fact that eEF2K activity can be negatively or positively associated with the 
translation rate of one and the same protein (such as BDNF) shows that the eEF2K-dependent 
regulation of the synaptic proteome is complex and depends on the specific signalling pathway 
involved. 
It is worthy to note that all of these publications demonstrate an involvement of the eEF2K/eEF2 
pathway exclusively at the excitatory postsynapse, mostly in response to acute stimulation of GluRs 
(see Fig. 3). This raises the question whether eEF2K is localized only to the subcellular 
compartment of excitatory synapses and primarily changes its activity in response to acute changes 
of GluR activity or whether simply further research is needed to have a more comprehensive view 
of  the eEF2K/eEF2 pathway at the synapse. For example, is eEF2K also important for the 
functionality of the GABAergic postsynapse and is the eEF2K/eEF2 pathway also located in the 
presynaptic compartment or is its synaptic localization limited to the postsynaptic compartment? 
What about somatically localized eEF2K activity, does it affect the pre- and postsynaptic 
compartment? And does a chronic change in eEF2K activity (as opposed to an acute change in 
eEF2K activity) have implications for the functionality of the synapse, as well? To the best of our 
knowledge, there are no publications focusing on these and other important questions which are 
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relevant to address in order to have a more complete understanding of what the eEF2K/eEF2 
pathway does at the synapse. 
 
 
 
Figure 3: The eEF2K/eEF2 pathway at the excitatory postsynapse can be actively modulated by GluR signalling. NMDAR or mGluR activation 
induces an increase in eEF2K activity which is associated with proteomic changes that, subsequently, lead to changes in synaptic structure and 
function. For example, mEPSC-mediated activation of NMDARs leads to an influx of Ca2+ and an increase in eEF2K activity which then induces a 
downregulation of BDNF and (surface) AMPAR levels. Consequently, AMPAR-mediated currents are reduced. It is important to note that even 
though activation of eEF2K leads to a downregulation of global protein translation, at the chemical synapse eEF2K activity is positively correlated 
with a subset of proteins such as MAP1b and Arc. Curiously, it is not known whether eEF2K activity is also presynaptically localized or whether it 
has an effect on presynaptic functions such as SV release. 
 
1.4 Aim of the study 
 
As mentioned in the previous section, the effect that eEF2K activity has on the synapse is probably 
underestimated since most research has focused on changes in eEF2K activity at the excitatory 
postsynapse in response to acute alterations in GluR activation. However, since synapses are crucial 
signalling-elements in neurons and neural networks and because many synaptic events depend on 
protein translation, it is important to have a better understanding of what the eEF2K/eEF2 pathway 
does at the synapse.  
Importantly, even though acute changes in eEF2K activity have been addressed, there is an 
incomplete view of what kind of effect chronic changes in eEF2K activity have on synapses, 
neurons, and neural networks. Accordingly, we decided to analyze what kind of functional and 
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proteomic effects chronic alteration and chronic absence of eEF2K activity have on neuronal and 
network processes, synapses, and synaptic events such as signal transmission at the chemical 
synapse. This analysis was mainly carried out by employing an in vitro eEF2K-gain-of-function 
design (primary neuronal cultures) and an in vivo loss-of-function design (eEF2K-KO mice). 
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2. Materials and methods 
 
 
2.1 Materials 
 
 
2.1.1 Animals 
 
To prepare primary neuronal rat cultures, pregnant female rats (Rattus norvegicus) of the phylum 
Wistar were purchased from Charles River (Charles River Laboratories, Calco, Italy). eEF2K-KO 
and Syn I, II, III triple knock-out (TKO) mice were re-derived on a C57BL/6 background (Charles 
River Laboratories, Calco, Italy). Mice and rats were housed under constant temperature (22 ± 1°C) 
and humidity (50%) conditions with a 12 h light/dark cycle, and were provided with food and water 
ad libitum. For proteomic and electrophysiological analysis of eEF2K-KO mice, male littermates 
between postnatal day (P) 30-42 were used, whereas for electroencephalography (EEG) and 
behavioural analysis 3-4-month-old male mice were used. 
All experiments involving animals followed protocols in accordance with the guidelines established 
by the European Communities Council and the Italian Ministry of Health (Rome, Italy). 
Experimental procedures of EEG and behavioural analysis followed the guidelines established by 
the Italian Council on Animal Care and were approved by the Italian Government decree No. 
17/2013. Animal experiments involving TKO mice were approved by the Institutional Animal Care 
and Use Committee of the San Raffaele Scientific Institute (Milan, Italy; IACUC permission no. 
565). All efforts were made to minimize the number of subjects used and their suffering.  
 
2.1.2 Biochemical substances, chemical substances, and equipment 
 
Biochemical substances, chemical substances, and equipment were purchased from the 
manufacturer initially listed. When not stated otherwise, chemicals were aquired from Sigma-
Aldrich. 
 
2.1.3 Antibodies 
 
Primary antibodies: 
Antibody Origin, immunogen Dilution Manufacturer 
anti (β-)actin slightly modified β-cytoplasmic actin N-
terminal peptide, Ac-Asp-Asp-Asp-Ile-
Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-
Gly-Lys, conjugated to KLH 
WB:  
1: 1,000 
Sigma-Aldrich 
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anti Caspase-3 rabbit, synthetic peptide which 
corresponds to residues around the 
cleavage site of human caspase-3 
WB:  
1: 1,000 
Cell Signalling 
anti eEF2 rabbit, synthetic peptide which 
corresponds to residues N-terminally of 
human eEF2 
WB:  
1: 400 
Cell Signalling 
anti eEF2K rabbit, synthetic peptide which 
corresponds to residues at the N-terminus 
of human eEF2k 
WB: 
1: 400 
Cell Signalling 
anti eEF2K rabbit, synthetic peptide which 
corresponds to residues at the N-terminus 
of human eEF2k 
IF: 
1:50 
Thermo 
Scientific 
anti GABAARα1 mouse, aa 355-394 of mouse GABAARα1 WB: 
1: 1,000 
IF: 
1: 500 
NeuroMab 
anti GAD65 mouse, synthetic peptide which 
corresponds to aa 4-22 of human GAD65 
IF:  
1: 500 
Abcam 
anti GAPDH rabbit, synthetic peptide which 
corresponds to residues at the N-terminus 
of mouse GAPDH, aa 314-333 
WB: 
1: 2,000 
Sigma-Aldrich 
anti GFP mouse, partially purified recombinant 
Aequorea victoria GFP 
WB:  
1: 1,000 
Roche 
anti GluR1 rabbit, KLH-conjugated linear peptide 
which corresponds to human GluR1 at the 
C-terminus 
WB: 
1: 1,000 
IF: 
1: 200 
Millipore 
anti MAP1b rabbit, MAP1B fusion protein ag16255 WB:  
1: 1,500 
Proteintech 
anti MAP2 mouse, bovine MAP2 IF: 
1: 400 
Abcam 
anti NLGN1 mouse, fusion protein with aa 551-640 of 
human NLGN1 
WB: 
1: 10,000 
NeuroMab 
anti peEF2 rabbit, synthetic phosphopeptide which 
corresponds to residues around Thr56 of 
human eEF2 
WB:  
1: 500 
Cell Signalling 
anti PSD95 mouse, aa 77-299 of human PSD95 WB:  
1: 5,000 
IF: 
1: 400 
NeuroMab 
anti Syp mouse, rat retina synaptosome WB: 
1: 200 
Sigma-Aldrich 
anti Syn mouse, partially purified Syn2b from N-
terminal region 
WB: 
1: 1,000 
home made 
antibody 
(Vaccaro et al., 
1997) 
anti Syn1/2 rabbit, synthetic peptide which 
corresponds to aa 2-28 in rat Syn 
IF: 
1: 400 
Synaptic 
Systems 
anti Syn2 mouse, partially purified Syn2b from N-
terminal region 
WB: 
1: 1,000 
home made 
antibody 
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(Vaccaro et al., 
1997) 
anti TRIM3 rabbit, synthetic peptide from N-terminal 
residues of human TRIM3  
WB: 
1: 200 
Abcam 
anti (α-)tubulin Sarkosyl-resistant filaments from 
Strongylocentrotus purpuratus (sea 
urchin) sperm axonemes 
WB:  
1: 1,000 
Sigma-Aldrich 
anti VGAT rabbit, synthetic peptide which 
corresponds to aa 75-87 in rat VGAT 
IF: 
1: 200 
Synaptic 
Systems 
anti VGLUT rabbit, fusion protein containing rat 
VGLUT, aa 456-560 
IF: 
1: 200 
Synaptic 
Systems 
 
Secondary antibodies: 
Antibody Origin Dilution Manufacturer 
anti mouse IgG, 
peroxidase-
conjugated 
goat WB 
1: 5,000 
Jackson 
ImmunoResearch 
Laboratories 
anti mouse IgG, 
680RD 
goat WB: 
1: 15,000 
LI-COR 
anti mouse IgG, 
FITC 
 IF: 
1: 100 
Jackson 
ImmunoResearch 
Laboratories 
anti mouse IgG, 
Cy3 
goat IF: 
1: 200 
Jackson 
ImmunoResearch 
Laboratories 
anti mouse IgG, 
Cy5 
goat IF: 
1: 100 
Jackson 
ImmunoResearch 
Laboratories 
anti rabbit IgG, 
peroxidase-
conjugated 
goat WB 
1: 5,000 
Jackson 
ImmunoResearch 
Laboratories 
anti rabbit IgG, 
800RD 
goat WB: 
1: 15,000 
LI-COR 
anti rabbit IgG, 
FITC 
 IF: 
1: 100 
Jackson 
ImmunoResearch 
Laboratories 
anti rabbit IgG, 
Cy3 
goat IF: 
1: 200 
Jackson 
ImmunoResearch 
Laboratories 
anti rabbit IgG, 
Cy5 
goat IF: 
1: 100 
Jackson 
ImmunoResearch 
Laboratories 
 
 
2.1.4 DNA constructs and vectors 
 
GFP and eEF2Kca lentiviral constructs were previously described (Verpelli et al., 2010) and are 
expressed by the previously described 2
nd
 generation lentiviral transfer vector FUW (Lois et al., 
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2002). K170M was subcloned into the FUW vector using the restriction sites BamH1 and Asc1. 
The sieEF2K/siRNA 362 lentiviral construct was also previously described (Verpelli et al., 2010) 
and is expressed in the previously described 2
nd
 generation lentiviral transfer vector pLVTHM 
(Wiznerowicz and Trono, 2003). It exhibits the following siRNA nucleotide sequence: 
gggagtggctgaaagacga. A scrambled form of sieEF2K was cloned into pLVTHM and exhibits the 
following nucleotide sequence: gctgagcgaaggagagat. sreEF2K  was designed on the basis of rat 
eEF2K in the pEGFP-C1 vector by Polymerase chain reaction (PCR)-mutagenesis. It was then 
subcloned into the 3
rd
 generation lentiviral transfer vector pUltra-hot (“Plasmid 24130: pUltra-hot”. 
Addgene, n.p., n.d, Web. 17 Dec. 2013; Addgene plasmid 24130;  principal investigator: Malcolm 
Moore) using the restriction sites Xba1 and Sal1. Its resistance to sieEF2K is due to 6 mutations 
(made evident by bold type) in the siRNA nucleotide sequence which conserves the peptide 
sequence in the corresponding region of the gene: gagaatggttaaaggatga. Syn2b was subcloned into 
the FUW vector using the restriction sites BamH1 and Asc1. All restriction enzymes were 
purchased by New England Biolabs. 
 
2.1.5 Acknowledgment of materials, corresponding researchers and 
associated institutions 
 
The NLGN1 antibody was a gift from Dr. N. Brose (Max Planck Institute of Experimental 
Medicine, Göttingen, Germany). The Syn antibody was a gift from Dr. Valtorta (Division of 
Neuroscience, San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy). The Syn2 
antibody was a gift from O. Franco (University of Genova, Genova, Italy). K170M cDNA was 
kindly provided by Dr. Chris G. Proud, (University of Southhampton, Southhampton, U.K.). Syn2b 
cDNA was kindly provided by George J. Augustine (Nanyang Technological University, 
Singapore, Singapore). The pUltra-hot vector was provided by Dr. M. A. S. Moore (Memorial 
Sloan-Kettering Cancer Center, New York, USA) via the webservice Addgene. Homozyguous 
eEF2K-KO mice were provided by Dr. Ryazanov (University of Medicine and Dentistry of New 
Jersey/Robert Wood Johnson Medical School, New Brunswick, NJ). TKO mice cultures were 
kindly provided by Dr. Flavia Valtorta (Division of Neuroscience, San Raffaele Scientific Institute 
and Vita-Salute University, Milan, Italy). TKO mice were provided by Dr. H.T. Kao (Brown 
University, Providence, RI, USA), and Dr. Paul Greengard (The Rockefeller University, NY, USA). 
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2.2 Methods 
 
Methods were carried out according to cited publications, common protocols, and protocols 
provided by manufacturer. Important changes in protocoles are noted and described. 
 
2.2.1 Cell culture 
 
Principally, rat primary hippocampal and cortical cultures of days in vitro (DIV) 20 were used. 
Alternatively, mouse hippocampal cultures of DIV 20 were used (always noted).  
2.2.1.1 Preparation of primary rat neuronal cultures 
 
Primary rat neuronal cultures were prepared similarly to a previously described study (Verpelli et 
al., 2010) with slight modifications. Hippocampal or cortical neuron cultures were prepared from 
embryonic day (E) 18 rat embryos (Charles River). Neurons were plated at medium density (200 
cells/mm²) on 12-well plates (Euroclone) with or without coverslips (VWR), coated with 0.01 
mg/ml poly-L-Lys (Sigma-Aldrich), and cultured using home made B27 which represents a slight 
variation of a previously described formula (Chen et al., 2008). Every week (at DIV 4, 11, and 18), 
40% of the volume was aspired and replaced by fresh medium (volume: 50% of the original 
volume). 12-well plates without coverslips were used for protein biochemical analysis, whereas 12-
well plates with coverslips were used for immunocytochemical or electrophysiological analysis. 
2.2.1.2 Preparation of primary mouse neuronal cultures 
 
Primary mouse neuronal cultures were prepared from the hippocampi of E 17.5 embryos from wild 
type (WT) and TKO mice as previously described (Banker and Cowan, 1977). Neurons were plated 
at medium density (200 cells/mm²) on 12-well plates (Corning, NY, USA) with or without 
coverslips (VWR), and coated with 0.1 mg/mL poly-L-Lys (Sigma-Aldrich). Cells were plated in 
complete Neurobasal medium [Neurobasal (Invitrogen, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum, 2% B27, 1% Pen/Strep, 1% L-Glutamax (Gibco ® Invitrogen)]. After 4 h, 
the medium was completely substituted with serum-free Neurobasal. Every week (at DIV 4, 11, and 
18), 30% of the volume was aspired and replaced by fresh medium (volume: 40% of the original 
volume). 12-well plates without coverslips were used for protein biochemical analysis, whereas 12-
well plates with coverslips were used for electrophysiological analysis. 
2.2.1.3 Lentiviral production and infection of primary rat and mouse neuronal 
cultures 
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Genetically modified lentiviruses were produced as previously described (Naldini et al., 1996; Lois 
et al., 2002) and the production was carried out with 2
nd
 and 3
rd
 generation lentiviral transfer 
vectors. Mainly, lentiviral infection took place at DIV 1. If infection took place at another time 
point, it is noted.  
2.2.1.4 Analysis of primary rat and mouse neuronal cultures 
 
Protein biochemical, immunocytochemical, or electrophysiological analysis was carried out at DIV 
20 unless otherwise stated. 
 
2.2.2 Protein biochemistry 
 
2.2.2.1 Preparation of samples 
 
Cultured neurons or brain lysates were collected with precooled “buffered sucrose” [0.32 M sucrose 
(Sigma-Aldrich)/4mM HEPES-NaOH buffer (Sigma-Aldrich), pH 7.3, protease inhibitors (Roche)] 
and analyzed via Bradford protein assay (Bio-Rad) to asses protein concentration. For total lysate 
(TL), proteins were solubilized in 2-4x loading buffer/dye [(250 mM Tris, 8 % (w/v), 40 % (v/v) 
glycerol, 0.008 % (w/v) bromophenol blue (all Sigma-Aldrich)] in order to have a final protein 
concentration of 1 µg/µl in the sample. In other cases, fractionation took place prior to Bradford 
protein assay analysis resulting in a P1 fraction (enriched in cell bodies and dendritic fragments) 
and a P2 fraction (enriched in presynaptic and postsynaptic components) (Huttner et al., 1983; 
Grabrucker et al., 2011). Also in the case of P1 and P2 fractions, 2-4x loading buffer was added in 
order to have a final protein concentration of 1 µg/µl in the sample. When not stated otherwise, 
samples are from TL. Samples were then heated for 5 min at 95°C (thermoblock from FALC 
Instruments) and centrifuged for 1 min at 15,000 g (centrifuge purchased from VWR, model 521-
3600). Then, 20 µg of samples were loaded in the pockets of 6-15% polyacrylamide gels (home 
made with reagents from Bio-Rad) and proteins were electrophoretically seperated by sodium 
dodecyl sulfate-Polyacrylamide gel electrophoresis (SDS-PAGE). 
2.2.2.2 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
electroblotting 
 
Proteins were electrophoretically seperated by SDS-PAGE under denaturing conditions (Laemmli, 
1970) followed by electroblotting of the proteins onto a nitrocellulose membrane using the Trans-
Blot Turbo System (Bio-Rad). Then the membranes were stained by Ponceau S Stain (Sigma-
Aldrich) to control for efficient protein transfer of proteins and were subsequently washed twice in 
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Tris-buffered saline-Tween (TBS-T) [20 mM Tris pH 7.4, 150 mM NaCl (both Sigma-Aldrich), and 
0.1% Tween 20 (Bio-Rad)]. 
 
2.2.2.3 Western Blot analysis 
 
Blocking of membranes took place for at least 1.5 h at 4°C in blocking buffer (TBS-T and 5% dried 
nonfat milk). Primary antibodies were applied for 1-3 h in blocking buffer (here: with 3 instead of 
5% dried nonfat milk). For rat neuronal culture lysates (except for those lysates analyzed in the 
context of paragraph 3.1.5), HRP-conjugated secondary antibodies (Jackson ImmunoResearch 
Laboratories) were used in blocking buffer (here: with 3 instead of 5% dried nonfat milk) and 
chemiluminescence was induced using an ECL kit (GE Healthcare). For brain lysates and rat/mouse 
neuronal culture lysates analyzed in the context of paragraph 3.1.5, fluorophore coupled secondary 
antibodies (LI-COR) were used and signal detection took place using an Odyssey scanner (LI-COR) 
after completely drying the membrane. After each antibody incubation, 3 washes (10 min each) 
took place with TBS-T. For fluorophore coupled secondary antibodies, 2 additional washes (10 min 
each) were added with Tris-buffered saline (TBS) [20 mM Tris pH 7.4, 150 mM NaCl (both Sigma-
Aldrich)] to displace Tween 20 from the membrane in order to avoid fluorescence background 
signal. Immunoblot band intensity was quantified manually with ImageJ (US National Institutes of 
Health), an open source program. Normalization took place via actin for P1 and P2 samples. For 
TL, mainly tubulin was used for normalization; actin was only used fot TL normalization when P2 
fractions were run in parallel in the gel. 
 
2.2.3 Immunocytochemistry 
 
For immunocytochemical analysis, neurons were fixed in methanol at -20°C or with 4% 
paraformaldehyde and 4% sucrose for 5-10 min at room temperature [for FM-dye, 0.05% 
glutaraldehyde (VWR) were added additionally] and then washed 3 times (10 min for each wash) 
with PBS [136.8 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4 and 1.76 mM KH2PO4 , pH 7.4 (all 
Sigma-Aldrich)]. Then, primary antibodies [diluted in GDB buffer: 30 mM phosphate buffer, pH 
7.4, 0.2% gelatin, 0.5% Triton X-100, 0.8 M NaCl (all Sigma-Aldrich)] were applied for 1-3 h at 
room temperature. Secondary antibodies were also diluted in GDB buffer and applied for 1 h. After 
each antibody incubation, 3 washes (10 min each) took place with “high-salt buffer” [20mM 
Na2HPO4/NaH2PO4 and 0.5M NaCl, pH 7.4 (all Sigma-Aldrich)] and before mounting a final wash 
(for 10 min) was carried out with PBS. Before mounting, coverslips were briefly passed through 
ddH2O to dilute salts. 4',6-diamidino-2-phenylindole (DAPI) staining (Life Technologies) was 
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carried out for 2 min (DAPI diluted in PBS to a final concentration of 0.5 µg/ml) and took place 
during the washing steps before mounting.  
2.2.3.1 FM-Dye experiment 
 
FM-dye staining was carried out with slight variation of a previously described protocole (Hering et 
al., 2003). More specifically, neurons were incubated for 1 min at room temperature in 3 µM FM 4-
64FX (Molecular Probes) in high potassium buffer [90 mM KCl, 55 mM NaCl, 10 mM HEPES pH 
7.4, 10 mM glucose, 2.6 mM CaCl2, 1.3 mM MgCl2 (all Sigma-Aldrich)] or in Tyrode solution 
[3mM KCl, 145 mM NaCl, 10 mM HEPES pH 7.4, 10 mM glucose, 2.6mM CaCl2, 1.3 mM MgCl2, 
5 µM glycine (all Sigma-Aldrich)]. Then, 4-5 washes (3-5 min each) with Tyrode solution were 
carried out in the presence of 1 µM tetrodotoxin (TTX) before fixation. After fixation, 
immunocytochemical analysis followed as described in paragraph 2.2.3. 
2.2.3.2 Image acquisition and Processing 
 
Mounted coverslips were imaged with a confocal microscope (Zeiss 510 with Zeiss 63 x objective) 
at a resolution of 1024 x 1024 pixels. Images represent maximum intensity projections of five 
individual images taken at depth intervals of around 0.5 µm. Acquired images were then analyzed 
for puncta quantity and size sing ImageJ (analyze particles option, cutoff: 1 µm²). To analyze the 
GAD65 stain at the soma, a circle (30 µm diameter) was laid around the center of the DAPI stain 
and the average GAD65 stain was calculated. For the FM-dye stain, a MAP2 mask was generated 
on which the the average FM-dye signal was calculated. 
 
2.2.4 Analysis of proteins by Liquid chromatography–mass 
spectrometry/mass spectrometry 
 
After SDS-PAGE, gels were stained with home made colloidal Coomassie Brilliant Blue [20% 
methanol, 8% ammonium sulfate, 1.6% phosphoric acid, and 0.12% Coomassie G-250 (all Sigma-
Aldrich)]. Gel slices were excised from the gels sampling the entire length of the lanes (15 slices 
each). After reduction with 10 mM dithiothreitol (DTT) (Sigma-Aldrich) , alkylation with 55 mM 
Iodoacetamide and overnight tryptic digestion (Shevchenko et al., 2006), peptide mixtures were 
desalted and concentrated on home made C18 Stage Tips µC18 (Rappsilber et al., 2007) and 
injected in a capillary chromatographic system (EasyLC, Proxeon Biosystems, Odense, Denmark). 
Peptide separation occurred on a RP homemade 15-cm reverse phase (RP) spraying fused silica 
capillary column (75 µm i.d.), packed in house with 3-µm ReproSil-Pur 120 C18-AQ (Dr. Maisch 
GmbH, Germany). A gradient of eluents A (H2O with 2% v/v ACN, 0.5% v/v acetic acid) and B 
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(80% ACN with  0.5% v/v acetic acid) was used to achieve separation, from 7% B (at 0 min 0.2 
µL/min flow rate) to 40% B (in 70 min, 0.2 µL/min flow rate). The LC system was connected to an 
LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a 
nanoelectrospray ion source (Proxeon Biosystems, Odense, Denmark). Mass spectrometry (MS) 
and MS/MS spectra were acquired selecting the ten most intense ions per survey spectrum acquired 
in the orbitrap from m/z 300-1750 with 30.000 resolution. Target ions selected for the MS/MS were 
fragmented in the ion trap and dynamically excluded for 60s. Target values were 1,000,000 for 
survey scan and 100,000 for MS/MS scan. For accurate mass measurements, the lock-mass option 
was employed (Olsen et al., 2005). Technical replicates were conducted on the Liquid 
chromatography–mass spectrometry (LC-MS)/MS part of the analysis. 
 
 
2.2.5 Real-time polymerase chain reaction 
 
Total messenger RNA (mRNA) was analyzed by Real-time polymerase chain reaction (RT-PCR). 
For this, total RNA was extracted from primary rat cortical cultures infected with GFP or eEF2Kca 
at DIV 20, using the RNeasy Mini Kit and accompanying QIAshredder (Qiagen) according to the 
manufacturer’s instructions. Contaminating DNA in the sample was degraded by on-column 
incubation with DNaseI (Qiagen) for 15 min. 1 µg per sample was reverse-transcribed using the 
SuperScript III (Life Technologies, Inc.) in accordance with the manufacturer’s instructions. Gene 
expression was quantitatively analysed by amplification carried out with the ABI Prism 7000 
Sequence Detection System and SDS software version 1.2.3 (Applied Biosystems, Inc., CA, USA). 
The target sequences were amplified from 50 ng of cDNA in the presence of TaqMan Gene 
Expression Master Mix. The TaqMan™ primer and probe assays (Life Technologies, Inc.) were 
eEF2 (ID # Rn00820849_g1), MAP1b (ID # Rn01399486_m1), TRIM3 (ID # Rn01509048_m1), 
Slc32a1 (namely VGAT, ID # Rn00824654_m1), Syn2 (ID # Rn00569739_m1), Gad2 (namely 
GAD65, ID # Rn00561244_m1), Dlg4 (namely PSD95, ID # Rn00571479_m1); the 
glyceraldehyde-3-phosphate dehydrogenase (GADPH; ID # Rn99999916_s1) was used as 
endogenous control. All of the assays were tested and confirmed as compatible for use with 
GAPDH as an endogenous control. The 2
-∆∆CT
 method was used to calculate the results, thus 
allowing the normalization of each sample to the endogenous control, and comparison with the 
calibrator for each experiment (set to a value of 1), as described in the figure legends. 
 
2.2.6 Electrophysiology  
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2.2.6.1 In vitro experiments (primary rat/mouse neuronal cultures) 
 
Whole-cell patch clamp recordings were performed at room temperature from DIV 20 primary 
cortical or hippocampal neurons perfused with external solution containing (in mM): 130 NaCl, 2.5 
KCl, 2.2 CaCl2, 1.5 MgCl2, 10 D-glucose, 10 HEPES-NaOH (pH 7.4; osmolarity adjusted to 290 
mOsm) for mIPSCs or Krebs'–Ringer's–HEPES solution containing (in mM): 125 NaCl, 5 KCl, 1.2 
MgSO4, 1.2 KH2PO4, 2 CaCl2, 6 glucose, and 25 HEPES, pH 7.4 for mEPSCs. For mPSC 
recordings, blockers of voltage-dependent sodium channels (500 µM lidocaine) were included in 
the extracellular solution. This was done in combination with blockers for GABAARs (20 µM 
bicuculline) or blockers for NMDARs, AMPARs/Kainate receptors [3mM Kynurenic acid (KYN)] 
for mEPSC or mIPSC recordings, respectively. The composition of the intracellular solution was 
(mM): 126 K-gluconate, 4 NaCl, 1 EGTA, 1 MgSO4, 0.5 CaCl2, 3 ATP (magnesium salt), 0.1 GTP 
(sodium salt), 10 glucose, 10 HEPES-KOH (pH 7.3; osmolarity adjusted to 280 mOsm) for 
mEPSCs recordings or 140 mM CsCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, 10 mM HEPES-
CsOH, 2 mM ATP (disodium salt) (pH 7.3) for mIPSCs. Recordings were performed with an 
Multiclamp 700B amplifier (Axon CNS molecular devices, USA). Pipette resistance was 2-3 MΩ 
and series resistance was always below 20 MΩ. mEPSCs and mIPSCs were recorded at a holding 
potential of -70 mV over a period of 2-5 min, filtered at 2 kHz and digitized at 20 kHz using 
Clampex 10.1 software. Analysis was performed offline with Clampfit 10.1 software using a 
threshold crossing principle; detection level was set at 5 pA, and raw data were visually inspected to 
eliminate false events; cells with noisy or unstable baselines were discarded. mEPSC and mIPSCs 
population averages were obtained by aligning the events at the mid-point of the rising phase. The 
weighted decay time constant (Dt) of mEPSCs were calculated as described (Cingolani et al., 2008). 
2.2.6.2 Ex vivo experiments (slices of eEF2K-KO mice and slices thereof) 
 
WT and eEF2K-KO mice were anesthetized in a chamber saturated with chloroform and then 
decapitated. The brain was rapidly removed and placed in an ice-cold solution containing 220 mM 
sucrose, 2 mM KCl, 1.3 mM NaH2PO4, 12 mM MgSO4, 0.2 mM CaCl2, 10 mM glucose, 2.6 mM 
NaHCO3 (pH 7.3, equilibrated with 95% O2 and 5% CO2), and 3 mM KYN. Coronal hippocampal 
slices (thickness, 250–300 µm) were prepared with a vibratome VT1000 S (Leica) and then 
incubated first for 40 min at 36°C and then for 30 min at room temperature in artificial CSF (aCSF), 
consisting of (in mM) 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 25 mM 
glucose, and 26 mM NaHCO3 (pH 7.3, equilibrated with 95% O2 and 5% CO2). 
Slices were transferred to a recording chamber perfused with aCSF at room temperature at a rate of 
about 2 ml/min. Whole-cell patch-clamp electrophysiological recordings were performed with an 
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Multiclamp 700B amplifier (Axon CNS molecular devices, USA) using an infrared-differential 
interference contrast microscope. Patch microelectrodes (borosilicate capillaries with a filament and 
an outer diameter of 1.5 µm; Sutter Instruments) were prepared with a four-step horizontal puller 
(Sutter Instruments) and had a resistance of 3–5 MΩ. 
Spontaneously occuring IPSCs as well as tonic GABAergic currents were recorded at a holding 
potential of −65 mV with an internal solution containing 140 mM CsCl, 2 mM MgCl2, 1 mM 
CaCl2, 10 mM EGTA, 10 mM HEPES-CsOH, 2 mM ATP (disodium salt) (pH 7.3), and 5 mM QX-
314 (lidocaine N-ethyl bromide). Access resistance was between 10 and 20 MΩ; if it changed by 
>20% during the recording, the recording was discarded. 
All GABAergic currents were recorded in the presence of KYN (3 mM) in the external solution. 
For the recording of mIPSCs, lidocaine (500 µM) was added in the external solution. Currents were 
filtered at 2 kHz and digitized at 20 kHz using Clampex 10.1 software.  Analysis was performed 
offline with Clampfit 10.1 software. 
 
2.2.7 Electroencephalography analysis  
 
2.2.7.1 Preparation of mice for electroencephalography analysis 
 
WT and eEF2K-KO mice were anesthetized with an i.p. injection of 5% chloral hydrate dissolved 
in saline and given at a volume of 10 ml/kg. Four screw electrodes (Bilaney Consultants GMBH, 
Dusseldorf, Germany) were inserted bilaterally through the skull over cortex (anteroposterior, +2.0–
3.0 mm; left–right 2.0 mm from bregma) as previously described (Manfredi et al., 2009) according 
to brain atlas coordinates (Franklin and Paxinos, 2008); a further electrode was placed into the nasal 
bone as ground. The five electrodes were connected to a pedestal (Bilaney, Dusseldorf, Germany) 
and fixed with acrylic cement (Palavit, New Galetti and Rossi, Milan, Italy). The animals were 
allowed to recover for a week from surgery before the experiment. After surgery, EEG activity was 
recorded in a Faraday chamber using a Power-Lab digital acquisition system (AD Instruments, 
Bella Vista, Australia; sampling rate 100 Hz, resolution 0.2 Hz) in freely moving awake mice.  
2.2.7.2 Electroencephalography analysis under baseline conditions 
 
Basal cerebral activity was recorded continuously for 22 hours (form 5:00 pm to 16:00 pm).   A 
quantitative analysis of spectral power was processed using fast Fourier transform. Each  2-hour 
spectral power was calculated between 0 and 25 Hz, with a 0.2 Hz resolution, using the standard 
spectral power distribution: δ (0-4 Hz), θ (4.2-8 Hz), α (8.2-13 Hz) and β (13.2-25 Hz). Segments 
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with movement artifacts or electrical noise were excluded from statistical analysis. EEG traces were 
also analyzed for spike activity (number) as previously described (Manfredi et al., 2009). 
2.2.7.3 Electroencephalography analysis after administration of chemoconvulsant 
substances 
  
After 30 minutes of baseline, animals were given pilocarpine (300 mg/kg i.p.) or pentylenetatrazol 
(PTZ) (30 mg/kg i.p.) and immediately recorded for EEG activity. Atropine methylnitrate  (5 mg/kg 
i.p.) was given 30 min before pilocarpine to reduce peripheral cholinergic side effects. Behaviour 
and EEG traces were analyzed as previously described (Nosten-Bertrand et al., 2008) for 2 hours 
after drug treatment. Seizures were scored as Racine’s scale (1, mouth and facial movement; 2, head 
nodding; 3, forelimb clonus; 4, rearing with forelimb clonus; and 5, rearing and falling with 
forelimb clonus). The number of animals showing seizures (Racine scale 3-5), total number of 
seizures, the latency to the first seizure and lethality were also evaluated. 
In accordance with a previous study (Erbayat-Altay et al., 2008), EEG seizures were characterized 
as absence (Racine scale 1-2) when associated with rhythmic 4-6Hz sharp waves of spindle-like 
events; myoclonic seizures (Racine scale 3) consisting of whole body jerk and bilateral forelimb 
movements associated with solitary spike or polyspike and slow wave; generalized clonic or tonic 
seizures (Racine scale 4-5) [whole body jerks consisting of a train of spikes (clonic) or a voltage 
attenuation (tonic phase) which lasted 30-60 sec]. Rhythmic sharp waves, spikes or polyspike were 
characterized by an amplitude at least two times higher than baseline. Seizures were video-
monitored and reviewed off-line by a blinded independent investigator to exactly score the seizures. 
Lethality was monitored within 7 days after drug injection. 
 
2.2.8 Genotyping of mice 
 
For genotyping of mice, DNA was extracted from tails and analyzed by PCR as previously 
described (Gitler et al., 2004; Autry et al., 2011). 
 
2.2.9 Data analysis and figure display 
 
2.2.9.1 Data analysis and display 
 
Data is expressed as means ± SEM or percentage, was analyzed for statistical significance, and was 
displayed by Prism 5 software (GraphPad, San Diego, CA). If there were only two groups whose 
means were compared, a student’s t-test was carried out to assess statistical significance. The 
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accepted level of significance was p ≤ 0.05. In all cases with three or more groups, a one factorial 
analysis of variance (ANOVA) was calculated for the data and if group means differed in a 
significant manner (p ≤ 0.05), a post hoc Tukey test was calculated to assess statistical significance. 
The accepted level of significance for the post hoc test was p ≤ 0.05. 
2.2.9.2 Mass spectrometry data analysis by MaxQuant 
 
Raw data was processed with MaxQuant version 1.1.1.36. Peptides were identified from the 
MS/MS spectra searched against the uniprot_cp_rat_2011_07 database using the Andromeda search 
engine (Cox et al., 2011). Cysteine carbamidomethylation was used as fixed modification, 
methionine oxidation and protein N-terminal acetylation as variable modifications. Mass deviation 
for MS/MS peaks was set at 0.5 m/z units and a maximum of two missed cleavages was allowed. 
The peptides and protein false discovery rates (FDR) were set to 0.01; the minimal length required 
for a peptide was six amino acids; a minimum of two peptides and at least one unique peptide were 
required for high-confidence protein identification; for quantitative analysis the options Re-quantify 
and second peptide were selected. The lists of identified proteins were filtered to eliminate reverse 
hits and known contaminants. The statistical program Perseus – in the MaxQuant environment – 
was used for determining the Significance B with a Benjamini-Hochberg FDR < 5%. For SILAC 
analysis, quantification of the up- and downregulated proteins followed the criteria: 1. weighted 
mean ratio (eEF2Kca/GFP) of the protein exhibited the same sign (< > 1) in all experiments; 2. the 
weighted mean ratio was significant in at least two experiments (significance evaluated by 
Benjamini-Hochberg FDR < 5%); 3. the ratio count of the peptide was greater than 1 (minimum 
Ratio Count = 2); 4. SD of weighted mean ratio did not exceed 0.25. 
2.2.9.3 Figure display 
 
Figures were generated with Microsoft Office PowerPoint 2003 for Windows (Microsoft) in 
combination with Adobe Photoshop 6.0 for Windows (Adobe). 
 
2.2.10 Acknowledgement of experimenters and corresponding institutions 
 
Electrophysiological analysis was carried out by Dr. Luca Murru (CNR Institute of Neuroscience 
and Department of Pharmacology, University of Milan, Milan, Italy). EEG recordings and analysis 
was carried out by Dr. Luisa Ponzoni and Dr. Daniela Braida (Department of Medical Biotechology 
and Translational Medicine, University of Milan, Milan, Italy). Breeding of TKO mice and 
generation of TKO culture was carried out by Dr. Fabrizia Guarnieri (Division of Neuroscience, 
    
 
 
   28 
San Raffaele Scientific Institute and Vita-Salute University, Milan, Italy). Execution and analysis of 
mass spectrometry was carried out by Dr. Angela Cattaneo (Biomolecular Mass Spectrometry Unit, 
Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy). The first 
SILAC experiment was carried out by Dr. Chiara Verpelli (CNR Institute of Neuroscience and 
Department of Pharmacology, University of Milan, Milan, Italy). Technical Support for RT-PCR 
analysis was given by Dr. Roberta Benfante (CNR Institute of Neuroscience and Department of 
Pharmacology, University of Milan, Milan, Italy). The PCR for cloning Syn2b into the FUW vector 
was carried out by Emmanuela Toffolo (Department of Medical Biotechnology and Translational 
Medicine, University of Milan, Milan, Italy). Dr. Elisa Faggiani (Neuromuscular Diseases and 
Neuroimmunology, Neurological Institute Foundation Carlo Besta, Milan, Italy) helped in the 
genotyping of eEF2K-KO mice. 
Dr. Carlo Sala (CNR Institute of Neuroscience and Department of Pharmacology, University of 
Milan, Milan, Italy) provided expertise for the part regarding molecular biology, biochemistry, the 
in vivo work and corrected the text. Dr. Chiara Verpelli provided expertise for the part regarding 
biochemistry. Dr. Mariaelvina Sala (Department of Medical Biotechology and Translational 
Medicine, University of Milan, Milan, Italy) and Dr. Daniela Braida provided expertise for the part 
regarding the EEG analysis and behavioural studies. Dr. Roberta Benfante provided expertise for 
the part regarding RT-PCR. Dr. Angela Bachi (Biomolecular Mass Spectrometry Unit, Division of 
Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy) provided expertise for the 
part regarding the mass spectrometry experiments. Dr. Luca Murru provided expertise for the 
electrophysiological part of the study. Dr. Patrizia Rosa (CNR Institute of Neuroscience and 
Department of Pharmacology, University of Milan, Milan, Italy) and Dr. Silvia Bassani (CNR 
Institute of Neuroscience and Department of Pharmacology, University of Milan, Milan, Italy) 
provided expertise for the FM-dye experiment. 
 
   3 Results 
 
 
   29 
3 Results 
 
3.1 eEF2K gain-of-function experiments in vitro (primary rat/mouse 
neuronal cultures)  
 
3.1.1 eEF2K upregulates a small number of synaptic proteins while 
downregulating a subset of presynaptic vesicle-associated proteins 
 
Previous studies on eEF2K have shown that this Ca
2+
/Calmodulin dependent kinase diversely 
regulates the translation rate of a set of proteins at the excitatory postsynapse which is most 
probably due to its ability to phosphorylate and thereby inactivate its only known substrate eEF2. 
Importantly, eEF2K activity can be altered by acute and prolonged changes in neuronal activity 
suggesting that the eEF2K/eEF2 pathway may represent a way for neurons to decode neuronal 
activity and implement the type of proteomic changes required (Scheetz et al., 2000; Chotiner et al., 
2003; Davidkova and Carroll, 2007; Sutton et al., 2007; Park et al., 2008; Verpelli et al., 2010; 
Autry et al., 2011). 
To deepen our understanding of which synaptic proteins are regulated by chronic eEF2K activity 
we lentivirally overexpressed either a constitutively active form of eEF2K (eEF2Kca) described 
previously (Verpelli et al., 2010) or GFP as an infection control at DIV 1 in primary cultures of rat 
hippocampal neurons. At DIV 20, P2 crude synaptosomal fractions (fractions enriched in synaptic 
components) were prepared according to a previously described protocol (Li et al., 1996; Ohno et 
al., 2004) and were analyzed by mass spectrometry to identify changes in protein levels (Fig. 5 A). 
For this, we took advantage of a metabolic labeling method called stable isotope labeling in cell 
culture (SILAC) which yields more quantitative mass spectrometry results as opposed to label-free 
methods (Ibarrola et al., 2003; Ibarrola et al., 2004; Mann, 2006; Ong and Mann, 2006; Bachi and 
Bonaldi, 2008; Liao et al., 2008; Spellman et al., 2008; Zhang et al., 2012). In this context we also 
carried out a pilot experiment in which we verified that isotope integration was successful at about 
95% (Fig. 4). Additionally, we verified by WB that eEF2K and peEF2 levels were successfully 
modified by eEF2Kca overexpression (Fig. 5 C, E). We also analyzed Caspase-3 cleavage as an 
indication of cell viability/apoptosis (Porter and Janicke, 1999; Zhang and Bhavnani, 2006) and 
could not detect differences between the groups (Fig. 5 B, D).  
The SILAC-based mass spectrometry analysis was carried out on three independent experiments, 
each yielding about 1100 identified proteins in the P2 fractions. To identify proteins strongly 
regulated by eEF2K, stringent parameters were applied, revealing 4 up- and 32 downregulated 
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proteins (Tab. 1). To better understand which synaptic proteins are regulated by eEF2K, the list was 
reduced to members which have been shown to localize to the synapse namely eEF2, MAP1b, 
Tripartite motif-containing protein 3 (TRIM3), Cask, and Glypican 4 (Gpc4) (Hsueh et al., 1998; 
Tabuchi et al., 2002; Zalfa et al., 2003; Davidkova and Carroll, 2007; Hung et al., 2010; Verpelli et 
al., 2010; Dajas-Bailador et al., 2012; de Wit et al., 2013; Taha et al., 2013). The list of 
downregulated proteins was augmented by a revision of the raw data which revealed several 
downregulated presynaptic vesicle-associated proteins with stable trends, such as Syn2 (Valtorta et 
al., 1992; Medrihan et al., 2013), while major postsynaptic proteins were not affected (Tab. 2).  
 
 
 
Figure 4: Successful incorporation of isotopes in SILAC procedure. To investigate the labeling efficiency in our experimental design, hippocampal 
neurons were grown from DIV 0 to DIV 20 with labeled/”heavy” amino acids: isotopes “Lys4” and “Arg6” (Cambridge Isotope Laboratories, Inc). At 
DIV 20, neurons were lysed and loaded on an SDS-Page. Then, a section of the gel was digested with trypsin, and analyzed by LC-MS/MS. Raw files 
were processed by MaxQuant and statistical data analysis was done using the R software package (ver. 2.10.1). The average labeling efficiency was 
95% (N = 246; Bandwidth: 0.009905; incorporation rate of Arg: 93.6%; incorporation rate of Lys: 97.2%) 
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Figure 5: SILAC procedure and associated WB analysis to compare crude synaptosomal fractions of GFP and eEF2Kca. A, SILAC procedure. 
Primary cultures of rat hippocampal neurons were grown in media (I.) without or (II.) with labeled isotopes of Arg and Lys (from plating, i.e. DIV 0, 
onwards). Cultures were infected with lentiviruses at DIV 1 with either (I.) GFP as an infection control or (II.) eEF2Kca. At DIV 20, equal protein 
amounts of P2 lysates from GFP and eEF2Kca were mixed, subjected to an SDS-PAGE, and analyzed via mass spectrometry. Three independent 
experiments were performed. B, Cell viability appears comparable between analyzed groups of SILAC experiments. To assess cell 
viability/apoptosis, total lysates of DIV 20 neurons were analyzed by WB for Caspase-3 cleavage. C, WB analysis of fractions of GFP and eEF2Kca 
infected cells reveals successful induction of eEF2K gain-of-function and enrichment of synaptic proteins in P2 fraction. At DIV 20, total lysates 
(TL), nuclear fractions (P1), and crude synapotosomal fractions (P2) were analyzed by WB for peEF2, eEF2K, GFP, and NLGN1 D + E, 
Quantifications of band intensities of B and C, respectively (NLGN1, GFP, and eEF2K quantification not shown). Band intensity is normalized by 
actin. For B a Caspase-3 cleavage quotient was calculated (17 kDa band intensity of Caspase-3 corresponding to cleaved protein was devided by 
35kDa band intensity corresponding to full length protein). Vertical axis shows the mean fold change vs. uninfected cells or GFP, TL, respectively 
(uninfected cells or GFP, TL  set to a value of 1). Error bars are SEMs. At least four independent experiments were performed per condition. **, and 
*** p <  0.01, and 0.001 versus GFP, TL.  §§, and §§§ p < 0.01, and 0.001 versus GFP, P1. #, ##, and ### p < 0.05,  0.01, and 0.001 versus GFP, P2 
(ANOVA and post hoc Tukey test). 
 
 
Regula-
tion by 
eEF2K 
 
Weighted 
Mean 
Ratio 
(eEF2Kca/ 
GFP) 
SD of Weighted 
Mean Ratios 
Protein Name Common Name/ 
Abbreviation 
Uniprot 
Accession 
Code 
↑ 1.38 0.04 Tripartite motif-containing protein 3; Brain-
expressed RING finger protein; RING finger protein 
22 
Trim3;Berp;Rnf22 D4A8U3;O7
0277 
↑ 1.40 0.07 CDK108;Mu-crystallin homolog Crym Q9QYU4 
↑ 1.41 0.10 MAP1 light chain LC1;Microtubule-associated 
protein 1B;Neuraxin 
MAP1b F1LRL9;P15
205 
↑ 2.23 0.25 Elongation factor 2 eEF2 P05197 
 
↓ 0.39 0.01 H1d;Histone H1.2 H1f2;Hist1h1c P15865 
↓ 0.61 0.03 Serine hydroxymethyltrans-ferase Shmt2 Q5U3Z7 
↓ 0.28 0.03 Putative uncharacterized protein 
ENSRNOP00000042464;Putative uncharacterized 
protein Hist1h2bm;Putative uncharacterized protein 
Hist1h2bn;RCG23099;Putative uncharacterized 
protein Hist1h2bp;Putative uncharacterized protein 
Hist1h2bb;Histone H2B type 1;Putative 
uncharacterized protein 
Hist3h2ba;RCG34360;Putative uncharacterized 
protein Hist2h2be 
Hist1h2bm;Hist1h2bn;rCG_
23099;Hist1h2bp;Hist1h2bb
;Hist3h2ba;rCG_34360;Hist
2h2be 
D4A817;D4
ABS3;D3ZN
H4;D3ZLY9;
F1LS18;D3Z
8U0;D3ZW
M5;Q00715;
F1LP73;D3Z
NZ9;D3ZZP
9 
↓ 0.23 0.03 Histone H4;Osteogenic growth peptide H4ft;Hist1h4b;Hist1h4m;Hi
st4;Hist4h4 
P62804 
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↓ 0.23 0.03 Histone H3;Putative uncharacterized protein 
Hist1h3f;Putative uncharacterized protein 
Hist2h3c2;Putative uncharacterized protein 
LOC684762;RCG45187;RCG45215;RCG51970;Put
ative uncharacterized protein 
ENSRNOP00000060626;Putative uncharacterized 
protein ENSRNOP00000008328;Histone 
H3.3;Histone H3.1;Putative uncharacterized protein 
LOC691496;RCG33140;Putative uncharacterized 
protein ENSRNOP00000051699 
H3f3b;Hist1h3f;Hist2h3c2;
LOC684762;rCG_45187;rC
G_45215;rCG_51970;H3.3
b;LOC691496;rCG_33140 
B0BMY8;D3
ZJ08;D3ZK9
7;D3ZQN4;P
84245;Q6LE
D0;D4A0P4;
D3ZVW5 
↓ 0.24 0.03 Putative uncharacterized protein 
Hist1h1b;RCG23067 
Hist1h1b;rCG_23067 D3ZBN0 
↓ 0.35 0.04 Putative uncharacterized protein 
LOC685909;RCG35761, isoform CRA_b;Histone 
H2A.Z 
LOC685909;rCG_35761;H
2afz;H2az 
D4AEC0;P0
C0S7;D4A7
X2 
↓ 0.59 0.04 ICD-M;IDP;Isocitrate dehydrogenase [NADP], 
mitochondrial;NADP(+)-specific 
ICDH;Oxalosuccinate decarboxylase 
Idh2 P56574 
↓ 0.34 0.05 Histone H2A type 1;Histone H2A type 2-A;Histone 
H2A.2;Putative uncharacterized protein 
Hist2h2ac;RCG51861 
Hist2h2aa3;Hist2h2ac;rCG_
51861 
P02262;P0C
C09;D4ACV
3 
↓ 0.65 0.06 Putative uncharacterized protein Maoa;Amine 
oxidase [flavin-containing] A;Monoamine oxidase 
type A 
Maoa D3ZFS8;P21
396 
↓ 0.34 0.06 Putative uncharacterized protein 
682318;RCG23057;Putative uncharacterized protein 
ENSRNOP00000051151;Histone H2A type 1-
C;Histone H2A type 1-E;Histone H2A type 
4;Histone H2A, testis;Histone H2A type 1-
F;Histone H2A type 3;Histone H2A;Histone 
H2A.J;Putative uncharacterized protein 
H2afx;RCG57928 
682318;rCG_23057;RGD15
64767;H2afj;H2afx;rCG_57
928 
D3ZVK7;D3
ZZ29;P0C16
9;P0C170;Q0
0728;Q64598
;Q4FZT6;Q6
I8Q6;A9UM
V8;D3ZXP3 
↓ 0.66 0.08 Ornithine aminotransferase, 
mitochondrial;Ornithine--oxo-acid aminotransferase 
Oat P04182 
↓ 0.54 0.09 Putative uncharacterized protein;Putative 
uncharacterized protein Sfrs3;RCG61099, isoform 
CRA_b 
Sfrs3;Sfrs3_predicted;rCG_
61099 
Q0ZFS8;D3Z
L34 
↓ 0.51 0.10 Core histone macro-H2A.1;H2A.y;H2A/y;Putative 
uncharacterized protein H2afy 
H2afy F1LR17;Q02
874;D3ZKI7;
Q02874-
2;D3ZZ57 
↓ 0.67 0.11 Chromosome segregation 1-like (S. cerevisiae) 
(Predicted);Putative uncharacterized protein Cse1l 
Cse1l;Cse1l_predicted;rCG
_32309 
D3ZPR0 
↓ 0.62 0.12 AIR carboxylase;Multifunctional protein 
ADE2;Phosphoribosylaminoimidazole 
carboxylase;Phosphoribosylaminoimidazole-
succinocarboxamide synthase;SAICAR 
synthetase;Putative uncharacterized protein Paics 
Ade2;Airc;Paics P51583;D4A
763 
↓ 0.64 0.14 Putative uncharacterized protein Actbl2;Similar to 
cytoplasmic beta-actin (Predicted) 
Actbl2;rCG_44795;RGD13
09504_predicted 
D3ZRN3 
↓ 0.52 0.14 Acyl-CoA synthetase family member 2, 
mitochondrial 
Acsf2 Q499N5 
↓ 0.61 0.14 Aldehyde dehydrogenase, mitochondrial;ALDH 
class 2;ALDH1;ALDH-E2 
Aldh2 P11884;F1L
N88 
↓ 0.48 0.14 Glial fibrillary acidic protein Gfap F1LSI8;P478
19;P47819-2 
↓ 0.25 0.16 Glycogen phosphorylase, muscle 
form;Myophosphorylase 
Pygm P09812 
↓ 0.67 0.16 3,2-trans-enoyl-CoA isomerase, 
mitochondrial;Delta(3),Delta(2)-enoyl-CoA 
isomerase;Dodecenoyl-CoA isomerase;Dodecenoyl-
coenzyme A delta isomerase;Dodecenoyl-
Coenzyme A delta isomerase (3,2 trans-enoyl-
Coenzyme A isomerase) 
Dci;rCG_33892 P23965;Q68
G41 
↓ 0.45 0.17 Putative uncharacterized protein 
RGD1563668;Amphoterin;Heparin-binding protein 
p30;High mobility group protein 1;High mobility 
group protein B1;Putative uncharacterized protein 
Hmg1l1;RCG50935;Putative uncharacterized 
protein RGD1560584;Putative uncharacterized 
protein ENSRNOP00000045117;Putative 
uncharacterized protein 
ENSRNOP00000041486;Putative uncharacterized 
protein ENSRNOP00000043786;Putative 
uncharacterized protein 
RGD1563668;Hmg1;Hmg-
1;Hmgb1;Hmg1l1;rCG_509
35;RGD1560584;Hmgb1-
ps3 
D3ZL49;F1
MA29;P6315
9;D3ZCR3;D
3ZXR5;D4A
9T3;D3ZLG3
;D3Z7Z9;F1
LTL3;F1LN
G6;D3ZLA7;
D3ZYR6;D3
ZJN6;D3Z8A
3;D3ZWY0;
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ENSRNOP00000046511;Putative uncharacterized 
protein ENSRNOP00000044633;Putative 
uncharacterized protein 
ENSRNOP00000046375;Putative uncharacterized 
protein ENSRNOP00000062422;Putative 
uncharacterized protein 
ENSRNOP00000063848;Putative uncharacterized 
protein ENSRNOP00000050063;Putative 
uncharacterized protein 
ENSRNOP00000048413;Putative uncharacterized 
protein ENSRNOP00000055435;Putative 
uncharacterized protein 
ENSRNOP00000044484;Putative uncharacterized 
protein ENSRNOP00000063563;Putative 
uncharacterized protein 
ENSRNOP00000061953;Putative uncharacterized 
protein Hmgb1-ps3;Putative uncharacterized protein 
ENSRNOP00000038289;Putative uncharacterized 
protein ENSRNOP00000042728;Putative 
uncharacterized protein 
ENSRNOP00000039114;Putative uncharacterized 
protein ENSRNOP00000051063 
D3ZA18;D3
ZFH8;D3ZC
69;D3ZXP6;
D3ZZD8;D4
A2L7;D3ZG
W6;D4AEI9;
D4A4X8;D3
ZMK0;F1LX
Z8;F1LTK2;
D3ZRY5 
↓ 0.60 0.18 Vimentin Vim P31000 
↓ 0.37 0.18 Putatuive uncharacterized protein Cask Cask D4A5M4 
↓ 0.63 0.18 2,4-dienoyl-CoA reductase [NADPH];2,4-dienoyl-
CoA reductase, mitochondrial 
Decr;Decr1 Q64591 
↓ 0.69 0.18 Sideroflexin-5;Tricarboxylate carrier BBG-
TCC;Putative uncharacterized protein 
ENSRNOP00000054347 
Sfxn5 Q8CFD0;D4
A441 
↓ 0.25 0.18 Eukaryotic translation initiation factor 5;Putative 
uncharacterized protein 
ENSRNOP00000045192;Putative uncharacterized 
protein RGD1564400 
Eif5;RGD1564400 Q07205;D4A
EA4;D3ZRG
2 
↓ 0.76 0.19     E9PTV2 
↓ 0.65 0.21 Rhodanese;Thiosulfate sulfurtransferase;Putative 
uncharacterized protein Tst 
Tst P24329;D3Z
F47 
↓ 0.58 0.22 Glypican 4 Gpc4 Q642B0 
 
Table 1: List of eEF2K-regulated proteins in crude synaptosomal fractions. The mass spectrometry analysis was applied to three independent 
experiments and successfully identified about 1100 proteins in the P2 fractions in each round. Then, MaxQuant ver.1.1.1.36 and Perseus were used to 
highlight proteins whose relative quantity strongly changed in eEF2Kca. For this analysis, four different parameters were utilized: 1. weighted mean 
ratio (eEF2Kca/GFP) of the protein exhibited the same sign (<> 1) in all experiments; 2. the weighted mean ratio was significant in at least two 
experiments (significance evaluated by Benjamini-Hochberg FDR < 5%); 3. the ratio count of the peptide was greater than 1 (minimum Ratio Count 
= 2); 4. SD of weighted mean ratio did not exceed 0.25. The analysis revealed 4 up- and 32 downregulated proteins (ratio of eEF2Kca to GFP greater 
and smaller than one, respectively). The list is ordered by up- and downregulated proteins and SD of the weighted mean ratio. 
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Table 2: List of synaptic and presynaptic vesicle-associated proteins regulated by eEF2K. To better understand which synaptic proteins are 
regulated by eEF2K, we searched for proteins with well-established synaptic localization in the list of eEF2K-regulated  proteins in crude 
synaptosomal fractions  (Tab. 1). For the upregulated proteins the list therefore was reduced to eEF2, MAP1b, and TRIM-3, all of which have been 
described to be present at the synapse (though they are not exclusively localized to the synapses). For the downregulated proteins the list was reduced 
to Cask and Gpc4, both of which have a well-described presynaptic localization (though Cask is also found postsynaptically). Since this proteomic 
data suggested that eEF2K appears to downregulate proteins with presynaptic localization, we reviewed the raw data and found several 
downregulated presynaptic vesicle-associated proteins such as Syn2 (but not its family member Syn3 and only a very small downregulation of Syn1 
of about 9%), SYT1 (no info on other family members since they were not identified), and VGAT. Interestingly, the revision of the raw data also 
showed that major postsynaptic proteins such as Homer1 were not downregulated by eEF2K. The list shows the aforementioned regulated proteins, as 
well as some selected non-regulated proteins (bottom part of table). The list is ordered by SD of the weighted mean ratio. 
 
3.1.2 Protein regulation depends on eEF2K activity, does not take place at 
transcriptional level, and is complex 
 
Using the same experimental framework (infection DIV 1, analysis DIV 20) without SILAC 
labeling we verified the quantitative changes of selected eEF2K-regulated proteins by western 
blotting using primary cultures of rat cortical neurons (Fig. 6 A, B). This analysis allowed us to 
distinguish between the P1 and P2 fraction (P1 is the complementary fraction to P2 and is therefore 
relatively enriched in nuclear components) and also allowed us to discern between the two Syn2 
isoforms. We realized that the proteomic regulations can be whitnessed in both fractions and that 
actually Syn2b (and not Syn2a) levels were signficantly decreased in eEF2Kca (Fig. 6 A, B). We 
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also analyzed the mRNA levels of the proteins by quantitative real-time PCR and found no 
difference between GFP and eEF2Kca, suggesting that the proteins are not regulated at the 
transcriptional level (Fig. 7).  
We then generated a lentivirus expressing a catalytically inactive form of eEF2K (K170M) 
previously described (Pigott et al., 2012; Pyr Dit Ruys et al., 2012) which preserves endogenous 
peEF2 levels (Fig. 8 A, C). K170M lentiviral overexpression took place in the same experimental 
framework in combination with either an small interference ribonucleic acid (siRNA) of eEF2K 
called siRNA 362 (henceforth referred to as sieEF2K), which was previously described (Verpelli et 
al., 2010) or with a scrambled form of this siRNA (scrambled). In parallel, an overexpression of 
GFP or an sieEF2K-resistant form of eEF2K (sreEF2K) was carried out, as well (Fig. 8 A). 
Consecutive WB analysis was mainly focused on eEF2 and MAP1B as representatives of regulated 
proteins. We found that both MAP1b and eEF2 upregulation does not take place in K170M (Fig. 8 
A, C). Taken together, these results suggests that in hippocampal and cortical neurons the eEF2K-
regulated proteins become regulated due to the catalytic activity of eEF2K and not due to changes at 
the transcriptional level, indicating that the observed quantitative changes are probably due to 
changes at the translational level.  
Interestingly, we also noticed that MAP1B levels directly depend on the amount of eEF2K which is 
not the case for eEF2 since sieEF2K led to a downregulation of MAP1B (and was rescueable by 
sreEF2K) but not eEF2 (Fig. 8 A, B). This suggests that there may be different classes of proteins 
whose quantity changes differentially in response to a gain-of-function of eEF2K. To investigate 
this concept further, neurons were infected with GFP or eEF2Kca at DIV 1 or DIV 10 and analysis 
was carried out one week after infection (as opposed to 19 days after infection like in the principal 
experimental framework). We found that eEF2 upregulation only took place if the infection was at 
DIV 1 whereas MAP1B and peEF2 up- and Syn2b downregulation took place independently of 
infection time point (Fig. 9 A, B, C). This suggests that the proteomic changes induced by eEF2K 
overexpression probably take place within 1 week after infection. Furthermore, these results suggest 
that there may be proteins regulated by eEF2K which have a strict correlation with eEF2K and 
peEF2 levels (like MAP1b) while others (like eEF2) may be regulated in a more complex fashion.  
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Figure 6: WB confirmation of selected eEF2K-regulated synaptic proteins. A, eEF2K-regulated proteins (see Tab. 2) can be verified by WB. 
Primary cortical rat cultures were infected with lentiviruses at DIV 1. At DIV 20, nuclear fractions (P1) and crude synaptosomal fractions (P2) were 
analyzed by WB for eEF2, MAP1b, TRIM3, and Syn2. Selected proteins not regulated by eEF2K (PSD95, NLGN1, GluR1, GABAARα1, and Syp) 
are shown, as well. B, Quantifications of band intensities of A (only of regulated proteins and PSD95). Band intensities are normalized by actin. 
Vertical axis shows the mean fold change vs. GFP (GFP set to a value of 1). Error bars are SEMs. At least five independent experiments were 
performed per analyzed protein. * p < 0.05, ** p < 0.01 versus GFP (student’s t-Test).  
 
 
 
Figure 7: Quantitative RT-PCR analysis reveals that eEF2K does not regulate identified proteins at the level of transcription. Primary cortical rat 
cultures were infected with lentiviruses at DIV 1 with GFP or eEF2Kca. At DIV 20, lysates were analyzed by quantitative RT-PCR for selected 
eEF2K-regulated proteins (eEF2, MAP1, TRIM3, VGAT, Syn2, GAD65; see Fig. 11 for the regulation of GAD65) and a non-regulated protein (PSD-
95). mRNA levels were standardized by GAPDH. Vertical axis shows the mean fold change vs. GFP (GFP set to a value of 1). Error bars are SEMs. 
Three independent experiments were performed per analyzed gene. 
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Figure 8: eEF2K activity is necessary for eEF2K-dependent protein regulation to occur but the regulation is not strictly correlated with eEF2K 
activity for all proteins. A, WB analysis reveals that eEF2K activity is essential for the regulation of eEF2 and MAP1b levels but only MAP1b levels 
correlate strictly with eEF2K activity. Primary cortical rat cultures were infected with lentiviruses at DIV 1 with either an siRNA for eEF2K 
(sieEF2K) or a scrambled siRNA (scrambled). These infections were also carried out in combination with GFP, an sieEF2K resistant form of eEF2K 
(sreEF2K), or a catalytically inactive form of eEF2K (K170M). At DIV 20, lysates were analyzed by WB for peEF2, eEF2, MAP1b, eEF2K, and 
GFP. B + C, Quantifications of band intensities of A. Band intensities are normalized by tubulin. Vertical axis shows the mean fold change vs. 
scrambled (scrambled set to a value of 1). Error bars are SEMs. At least three independent experiments were performed per condition. *, **, and *** 
p < 0.05,  0.01, and 0.001 versus scrambled. §, §§, and §§§ p < 0.05,  0.01, and 0.001 versus scrambled+GFP. #, ##, and ### p < 0.05,  0.01, and 
0.001 versus scambled+sreEF2K or scrambled+K170M (B or C, respectively). @, @@, and @@@ p < 0.05,  0.01, and 0.001 versus sieEF2K. &, 
&&, and &&& p < 0.05,  0.01, and 0.001 versus sieEF2K+GFP (ANOVA and post hoc Tukey test). 
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Figure 9: eEF2K-dependent protein regulation is complex. A, WB analysis reveals that the timepoint of eEF2Kca infection has an effect on the 
levels of the eEF2K-regulated proteins eEF2 and MAP1b. Primary cortical rat cultures were infected with lentiviruses at DIV 1 or DIV 10 with GFP 
or eEF2Kca. One week after infection, lysates were analyzed via WB for peEF2, eEF2, MAP1b, and Syn2b. B + C, Quantifications of band 
intensities of A. Band intensities are normalized by tubulin. Vertical axis shows the mean fold change vs. GFP (GFP set to a value of 1). Error bars 
are SEMs. * p < 0.05, *** p < 0.001 versus GFP (student’s t-Test). 
 
3.1.3 eEF2K activity downregulates puncta of presynaptic vesicle-associated 
proteins and is most evident at the inhibitory synapse 
 
Since eEF2K activity downregulates the quantity of several presynaptic and presynaptic vesicle-
associated proteins, we wondered whether these effects would also be reflected by a change of their 
distribution and/or accumulation at the presynapse. At the same time we were curious to find out if 
eEF2K activity has differential effects on inhibitory and excitatory synapses. To this end, we carried 
out an immunocytochemical analysis in the aforementioned principal experimental framework 
(lentiviral infection of primary cortical rat cultures at DIV 1 fixation DIV 20) where we analyzed 
the puncta amount and puncta size of several pre- and postsynaptic markers of the GABAergic (i.e. 
inhibitory) and glutamatergic (i.e. excitatory) synapse: Syn1/2 (GABAergic/glutamatergic 
presynapse), VGAT (GABAergic presynapse), GAD65 (GABAergic presynapse), VGLUT 
(glutamatergic presynapse), as well as GABAARα1 (GABAergic postsynapse), GluR1 
(glutamatergic postsynapse), and PSD95 (glutamatergic postsynapse) (Lee et al., 2003; Castejon et 
al., 2004; Tafoya et al., 2006; Bragina et al., 2007; Bethmann et al., 2008; Gitler et al., 2008). 
Infection was carried out with GFP, eEF2Kca, or K170M in order to have an infection control and 
also a control of the catalytic activity of eEF2K. Qualitatively speaking, infection efficiency was at 
nearly 100% (Simmons et al., 2006) and Microtubule-associated protein 2 (MAP2) stainings 
seemed comparable between the groups, indicating that the basic morphology and microtubular 
organization in the neurons (and their dendritic compartments) is unaltered by eEF2K 
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overexpression (Fig. 10 A) (Hendry and Bhandari, 1992; Li et al., 2000; Teng et al., 2001; Chen et 
al., 2012). 
As expected from the proteomic results (see Fig. 6 A, B), a small but significant downregulation of 
both Syn1/2 puncta amount and puncta size was evident in eEF2Kca (relative to GFP and K170M). 
Judging by the proteomic results, our assumption is that the effect is mainly due to a 
downregulation Syn2b (see Tab. 2). Instead, the downregulation did not apply to costained PSD95. 
This suggests that eEF2K activity causes Syn1/2 molecules to be less abundant and/or less 
accumulated at the glutamatergic and GABAergic presynapse which, in turn, implicates functional 
changes in SV dynamics (Valtorta et al., 2011). This result also indicates that eEF2K activity does 
not have a big effect on the scaffold of the glutamatergic postsynaptic compartment (Sheng and 
Hoogenraad, 2007). Of notice, the (spatial) correlation of Syn1/2 and PSD95 puncta was not 
changed in the groups, which indicates that the basic organization of the glutamatergic synapse 
(namely the degree of juxtaposition of pre- and postsynapse) is unaltered by overexpressing eEF2K 
(Garner and Kindler, 1996; Castejon et al., 2004) (Fig. 10 B, C). Another result in line with the 
proteomic data is that we observed a downregulation of puncta of the vesicular GABA transporter 
VGAT in eEF2Kca (relative to GFP and K170M). Instead, this is not the case for the vesicular 
glutamate transporter VGLUT nor the postsynaptic GABAR and GluR subunits GABAARα1 and 
GluR1, respectively (Fig. 11 E, F). This means that eEF2K activity may have a strong effect on the 
uptake of GABA into synaptic vesicles while not affecting GABARs/GluRs or GABAR/GluR-
dependent events at the postsynaptic level which is in agreement with the results of the WB analysis 
(see Fig. 6 A). 
Since eEF2K activity downregulates VGAT puncta, we wondered whether this would also be 
observed with presynaptic markers which are functionally and biochemically associated with 
VGAT and are therefore colocalized with it. One such marker is GAD65 (Jin et al., 2003; Tafoya et 
al., 2006; Zander et al., 2010), a protein which was not identified in the mass spectrometry analysis, 
probably due to technical limitations (Wysocki et al., 2005). GAD65 is also of particular interest for 
understanding whether eEF2K activity has a significant effect on the presynaptic compartment of 
the inhibitory synapse (and the GABA system in general for that matter), since it is an enzyme 
critically involved in the presynaptic synthesis of GABA (Pinal and Tobin, 1998; Tian et al., 1999; 
Walls et al., 2010). Additionally, GAD65 allows one to discern between inhibitory and excitatory 
neurons because it is accumulated in the soma of GABAergic neurons, where it is actively 
synthesized (Kanaani et al., 2002; Mi et al., 2002). We noticed a clear downregulation GAD65 
puncta both in inhibitory and excitatory neurons. Inhibitory neurons also displayed a reduction in 
GAD65 puncta size and in the somatic signal of GAD65 (Fig. 11 A, B, C, D). This indicates that 
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eEF2Kca activity may have a strong effect on the inhibitory presynaptic compartment by 
downregulating GAD65 quantity and/or accumulation, thereby presumably reducing the availability 
of the inhibitory neurotransmitter GABA at the synapse and in SVs.  
Taken together, this data indicates that eEF2K gain-of-function in primary neuronal cultures leads 
to a downregulation of certain presynaptic vesicle-associated markers (like Syn1/2, VGAT, and 
GAD65) while leaving major postsynaptic markers (like PSD95, GABAARα1, and GluR1) 
associated with scaffolding and GABA/glutamate signalling unchanged. Therefore, eEF2K 
presumably does not change the general architecture or function of the postsynapse but instead 
probably has a strong impact on SV dynamics (and possibly SV content in the case of inhibitory 
presynaptic compartments). Of note, the fact that eEF2Kca only leads to a downregulation of a 
subset of synaptic proteins while leaving the amount of other synaptic proteins unchanged (see also 
Tab. 2) also indicates that the total amount of (functional) synapses is probably not altered by 
eEF2K activity but instead the function of each individual presynaptic compartment may very well 
be affected. 
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Figure 10: eEF2K activity downregulates puncta of vesicle-associated proteins of the inhibitory and excitatory presynapse but does not affect 
neuronal morphology, nor the basic organization of the excitatory postsynapse. A, High infection efficiency and comparable MAP2 stains of GFP, 
eEF2Kca, and K170M. Primary cortical rat cultures were infected with GFP, eEF2Kca, or K170M at DIV 1. At DIV 20 neurons were fixated and 
subjected to immunocytochemical analysis for eEF2K and MAP2 (costained). GFP reflects fluorescence of GFP reporter gene. Imaged neurons were 
selected at random. Scale bar, 100 µm. B, eEF2K activity leads to a reduction of Syn1/2 puncta and puncta size but does not affect PSD95 puncta, nor 
the correlation of Synapsin and PSD95 puncta. Primary cortical rat cultures were infected with GFP, eEF2Kca, or K170M at DIV 1. At DIV 20 
neurons were fixated and subjected to immunocytochemical analysis of Syn1/2 and PSD95 (costained). Images of entire neurons and one of their 
(straightened, magnified) dendrites are shown. Imaged neurons were selected on the basis of prominent Syn1/2 stains. Scale bar, 100 µm. Scale bar 
magnified image, 10 µm. C, Quantifications of puncta (amount), puncta size, and correlation of markers from B (quantifications carried out on image 
of entire neuron). Vertical axis shows the mean fold change vs. GFP (GFP set to a value of 1). Error bars are SEMs. At least six independent 
experiments (on average three imaged neurons per experiment) were performed per condition. *, ** p < 0.05 and 0.01 versus GFP. § and §§ p < 0.05 
and 0.01 versus eEF2Kca (ANOVA and post hoc Tukey test). 
 
 
 
Figure 11: eEF2K activity downregulates puncta of GABA-signalling- and vesicle-associated proteins of the inhibitory presynapse but does not 
affect postsynaptic GABA and glutamate receptors. A, eEF2K activity downregulates GAD65 puncta of excitatory neurons. Primary cortical rat 
cultures were infected with GFP, eEF2Kca, or K170M at DIV 1. At DIV 20 neurons were fixated and subjected to immunocytochemical analysis for 
GAD65. Imaging was restricted to cells without prominent GAD65 signal near DAPI stain (DAPI stain not shown). Scale bar, 100 µm. C, eEF2K 
activity downregulates GAD65 puncta and puncta size of inhibitory neurons, as well as the GAD65 signal at the soma of these cells. Primary cortical 
rat cultures were infected with GFP, eEF2Kca, or K170M at DIV 1. At DIV 20 neurons were fixated and subjected to immunocytochemical analysis 
for GAD65. Imaging was restricted to cells with prominent GAD65 signal near DAPI stain (DAPI stain not shown). Scale bar, 100 µm. E, eEF2K 
activity downregulates VGAT, but not VGLUT, GluR1, nor GABAARα1 puncta. Primary cortical rat cultures were infected with GFP, eEF2Kca, or 
K170M at DIV 1. At DIV 20 neurons were fixated and subjected to immunocytochemical analysis for VGLUT, VGAT, GluR1, and GABAARα1. 
Imaged neurons were selected on the basis of a prominent stain. Scale bar, 100 µm. B, D, F, Quantifications of puncta (amount) and puncta size from 
A, C, and E, respectively (also quantification of soma signal for C). Vertical axis shows the mean fold change vs. GFP (GFP set to a value of 1). Error 
bars are SEMs. At least five independent experiments (on average three imaged neurons per experiment) were performed per condition.  * and *** p 
< 0.05 and 0.001 versus GFP. § and §§ p < 0.05 and 0.01 versus eEF2Kca (ANOVA and post hoc Tukey test). 
 
3.1.4 eEF2K activity downregulates vesicle release  
 
Since our results strongly indicate that eEF2K activity downregulates presynaptic vesicle-associated 
proteins like Syn2b, we wanted to analyze whether this would also be reflected in functional 
changes of the presynaptic compartment. One of the described functions of Syns is the control of 
SV release (Sihra et al., 1989; Valtorta et al., 2011; Medrihan et al., 2013) so we were curious to see 
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if eEF2K activity downregulates vesicle release. We addressed this question with an FM-dye 
experiment, which gives an indication of vesicle release. It does so by the use of a fluorescent dye 
that binds to membranes and therefore becomes internalized into the neuron after vesicle release 
(which is made evident by activating the neurons) and associated endocytosis (Hering et al., 2003; 
He and Wu, 2007; Kim and Thayer, 2009; Saheki and De Camilli, 2012). Using a slightly modified 
experimental design previously described (Hering et al., 2003), we found that activated neurons 
release fewer vesicles in eEF2Kca than in GFP, whereas the release does not differ between GFP 
and K170M, indicating that eEF2K activity is responsible for a reduction of vesicle release. Of 
note, a separate analysis revealed that even under baseline conditions neurons release fewer vesicles 
in eEF2Kca than in GFP (Fig. 12 A, B).  
This result means that eEF2K activity, indeed, downregulates a central function of the presynaptic 
compartment, namely: eEF2K appears to downregulate vesicle release, presumably via its 
downregulation of vesicle-associated proteins like Syn2b. This reduction of vesicle release could be 
either due to eEF2K activity causing a reduction in the number of functional synapses or it could be 
due to eEF2K activity causing a reduction in the efficacy (i.e. release probability) of each individual 
presynaptic compartment. Judging by our immunocytochemical and proteomic results (see Tab. 2, 
Fig. 6, and paragraph 3.1.3), the latter possibility is more probable. 
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Figure 12: eEF2K activity downregulates vesicle release. A, eEF2K activity downregulates FM 4-64 FX dye incorporation following neuronal 
activation. Primary cortical rat cultures were infected with GFP, eEF2Kca, or K170M at DIV 1. At DIV 20 neurons were activated with high 
potassium buffer (right side of figure; “ACTIVATION”) or were treated with Tyrode solution as a (non-activated) control (left side of figure; 
“BASELINE”) (c.f. materials and methods). Neurons were then fixated and subjected to immunocytochemical analysis for MAP2. eEF2K was 
costained for eEF2Kca and K170M. GFP reflects fluorescence of GFP reporter gene. FM-dye reflects signal from FM 4-64 FX dye. Images of entire 
neurons and one of their (straightened, magnified) dendrites are shown. Imaging was restricted to cells with prominent GFP signal/ eEF2K stain. 
Scale bar, 100 µm. Scale bar magnified image, 10 µm. B, Quantification of A, mean pixel intensity of FM-dye on MAP2 mask (quantifications 
carried out on image of entire neuron). Vertical axis shows the mean fold change vs. GFP, baseline (GFP, baseline set to a value of 1). Error bars are 
SEMs. Three independent experiments (on average five imaged neurons per experiment) were performed per condition. *** p < 0.001 versus GFP, 
baseline. §, §§, and §§§ p < 0.05, 0.01, and 0.001 versus eEF2Kca, baseline or K170M, baseline (left or right quantification, respectively) (ANOVA 
and post hoc Tukey test). (*) p < 0.05 versus GFP, baseline (analysis only carried out for eEF2Kca, baseline and K170M, baseline) (student’s t-Test).  
 
3.1.5 eEF2K activity downregulates mPSC frequency by downregulating 
Syns/Syn2b and depotentiates mIPSCs 
 
To further examine the effect of eEF2K activity on vesicle release and the functionality of the 
synapse, we employed electrophysiology to analyse mPSCs in the aforementioned experimental 
framework (infection of rat cortical neurons with GFP, eEF2Kca, or K170M at DIV 1, recording 
DIV 20). A change in mPSC frequency can be due to a change in vesicle release probability (or the 
amount of functional synapses) and is therefore usually interpreted as a change in presynaptic 
function. Instead, a change in mPSC decay time, amplitude, and area/charge transfer is usually 
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interpreted as a functional change at the postsynapse, reflecting changes in kinetics, efficacy, or 
quantity of receptors, though a change in mPSC amplitude/area may also reflect a reduction in the 
amount of released neurotransmitters (Fatt and Katz, 1952; Van der Kloot, 1991; Queenan et al., 
2001; Tyler and Pozzo-Miller, 2001; Han and Stevens, 2009). Importantly, we also tested whether 
Syns -and the eEF2K-regulated isoform Syn2b in particular- are related to (and possibly the root 
cause of) eEF2K-induced changes of mPSC since there is literature indicating that changes in levels 
of Syn2b are related to changes in mPSCs (Gitler et al., 2008; Medrihan et al., 2013). 
We found that eEF2K activity markedly reduced the frequency of mEPSCs while leaving other 
mEPSC parameters unaffected (Fig. 13 A, B). Interestingly, the same phenomenon was observed in 
mouse primary hippocampal neurons infected with GFP or eEF2Kca (Fig. 14. A, B) while no 
difference in mEPSC frequency was detected between GFP and eEF2Kca in neurons derived from 
Syn 1-3 KO (TKO) mice (Fig. 14 A, B). Worthy of note, both in wildtype and TKO primary mouse 
hippocampal neurons eEF2Kca induced similar proteomic changes as observed initially in rat 
hippocampal and cortical neurons (Fig. 15. A, B; see also Fig. 6), indicating two things: firstly, 
eEF2K activity has a very general effect on the synaptic proteome and presynaptic function (here: 
reduction of mEPSC frequency), since similar eEF2K-induced changes can be observed in rat or 
mouse neuronal (i.e. cortical or hippocampal) cultures; secondly, the fact that eEF2Kca does not 
reduce mEPSC frequency in TKO cultures cannot be explained by a TKO-specific eEF2K-
dependent regulation of the proteome. These results indicate that eEF2K activity reduces mEPSC 
frequency by downregulating Syn levels. Importantly, we found that eEF2Kca does not reduce the 
frequency of mEPSCs when co-overexpressed with Syn2b (Fig. 16 A, B), indicating that eEF2K 
reduces mEPSC frequency by downregulating Syn2b levels. 
We also found that eEF2K activity reduced the frequency of mIPSCs, however, also the decay time, 
area, and amplitude were markedly reduced (Fig. 13 A, B). In mouse hippocampal neurons mIPSC 
frequency and decay time were reduced (Fig. 14 A, B). Instead, no differences in mIPSC frequency 
were detected between GFP and eEF2Kca in neurons derived from TKO mice but the reduction in 
mIPSC decay time took place, nonetheless (Fig. 14 A, B). These results indicate that eEF2K 
activity reduces mIPSC frequency by downregulating synapsin levels, whereas mIPSC decay time 
(and possibly the other mIPSC parameters) are reduced in a synapsin-independent fashion. 
Taken together, these results indicate that eEF2K activity reduces mPSC frequency and therefore 
probably reduces release at the excitatory and inhibitory presynapse (we exlude the possibility of a 
change in the amount of functional synapses, see Tab. 2, Fig. 6, and paragraph 3.1.3). This effect 
appears to be mediated by the downregulation of the Syn family and Syn2b in particular. Instead, 
eEF2K does not appear to affect the efficacy of ionotropic GluRs at the excitatory postsynapse 
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since mEPSC decay time, area, and amplitude are unchanged. On the contrary, eEF2K activity does 
appear to downregulate GABAAR kinetics/efficacy at the inhibitory postsynapse since the mIPSC 
decay time is downregulated and this effect presumably occurs in a Syn-independent manner. In rat 
cortical cultures, eEF2K activity additionally leads to a downregulation of mIPSC area and 
amplitude. This may reflect a downregulation of GABAAR efficacy and/or quantity but it may also 
reflect a downregulation of GABA in the GABAergic vesicles (see Fig. 11). 
 
 
 
Figure 13: eEF2K activity downregulates mPSC frequency and depotentiates mIPSCs. A, eEF2K activity downregulates mEPSC and mIPSC 
frequency but also downregulates mIPSC decay time, area, and amplitude. Primary cortical rat cultures were infected with GFP, eEF2Kca, or K170M 
at DIV 1. At DIV 20 neurons were subjected to electrophysiological analysis of mPSCs. Neurons were chosen at random for recordings. 
Representative traces of mEPSCs (I.) and mIPSCs (II.) are shown for GFP, eEF2Kca, and K170M B, Quantification of A. Vertical axis shows Hz (for 
frequency), ms (for decay time), pA*ms (for area), and pA (for amplitude). Error bars are SEMs. Three independent experiments (on average seven 
recorded neurons per experiment) were performed per condition. * and *** p < 0.05 and 0.001 versus GFP. §§§ p < 0.001 versus eEF2Kca (ANOVA 
and post hoc Tukey test).  
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Figure 14: eEF2K-dependent mPSC frequency downregulation is Syn-dependent but the mIPSC depotentiation is not. A, eEF2K downregulates 
mEPSC and mIPSC frequency but also downregulates mIPSC decay time. Primary hippocampal mouse cultures (WT and TKO) were infected with 
GFP or eEF2Kca at DIV 1. At DIV 20 neurons were subjected to electrophysiological analysis of mPSCs. Neurons were chosen at random for 
recordings. Representative traces of mEPSCs (I.) and mIPSCs (II.) are shown for GFP, WT/TKO and eEF2Kca, WT/TKO B, Quantification of A. 
Vertical axis shows Hz (for frequency), ms (for decay time), pA*ms (for area), and pA (for amplitude). Error bars are SEMs. Three independent 
experiments (on average six recorded neurons per experiment) were performed per condition. * and ** p < 0.05 and 0.01 versus GFP, WT. § and §§ p 
< 0.05 and 0.01 versus eEF2Kca, WT. # p < 0.05 versus GFP, TKO (ANOVA and post hoc Tukey test).  
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Figure 15: eEF2K overexpression induces similar proteomic changes in WT and TKO hippocampal mouse cultures as in rat cortical/hippocampal 
cultures. A, WB analysis reveals that eEF2Kca induces an upregulation of eEF2 and MAP1b while downregulating Syn2b. Primary hippocampal 
mouse cultures (WT and TKO) were infected with lentiviruses at DIV 1 with GFP or eEF2Kca. At DIV 20, lysates were analyzed via WB for peEF2, 
Syn, eEF2, MAP1b, and Syn2b. B, Quantifications of band intensities of A. Band intensities are normalized by tubulin. Vertical axis shows the mean 
fold change vs. GFP WT/TKO (GFP WT/TKO set to a value of 1). Error bars are SEMs. Three independent experiments were performed per 
condition. * and ** p < 0.05, and  0.01 versus GFP WT/TKO (student’s t-Test). 
 
 
 
Figure 16: eEF2K reduces mEPSC frequency via Syn2b. A, Syn2b co-overexpression with GFP or eEF2Kca is comparable in terms of observed 
Syn2b levels. Primary cortical rat cultures were infected with GFP alone, GFP and Syn2b, eEF2Kca alone, eEF2Kca and Syn2b, or Syn2b alone at 
DIV 1. At DIV 20 neurons were analyzed by WB for peEF2 or Syn2b (quantification not shown). B, Syn2b co-overexpression can rescue eEF2K-
mediated mEPSC frequency downregulation. Primary cortical rat cultures were infected with GFP alone, GFP and Syn2b, or eEF2Kca and Syn2b at 
DIV 1. At DIV 20 neurons were subjected to electrophysiological analysis of mEPSCs. Neurons were chosen at random for recording. 
Quantifications (but not representative traces) are shown. Vertical axis shows Hz (for frequency), ms (for decay time), pA*ms (for area), and pA (for 
amplitude). Error bars are SEMs. Three independent experiments (on average four recorded neurons per experiment) were performed per condition. 
** p < 0.01 versus GFP. § < 0.05 versus GFP and Syn2b (ANOVA and post hoc Tukey test).  
 
 
 
 
3.2 eEF2K loss-of-function in vivo and ex vivo (eEF2K-KO mice and 
slices thereof) 
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3.2.1 eEF2K-KO mice exhibit increased Syn2b expression levels 
 
To examine correlates of our in vitro results in vivo/ex vivo we chose to examine previously 
described eEF2K-KO mice (Ryazanov, 2002), i.e. we chose a chronic loss-of-function design in 
which we expected opposite effects of the (chronic) gain-of-function experiments in vitro. Genetic 
deletion of eEF2K activity in vivo causes no obvious phenotypes in mice (normal weight and 
behaviour, normal baseline brain activity levels and excitatory transmission, intact incidental 
learning) despite a profound reduction in peEF2 levels, though there is literature demonstrating 
impairments in synaptic plasticity and associative learning (Ryazanov, 2002; Park et al., 2008; 
Gildish et al., 2012; Nosyreva et al., 2013). Of note, there are also publications which show that the 
eEF2K/eEF2 pathway is involved in stress-responses both in vitro and in vivo (Dorovkov et al., 
2002; Dagestad et al., 2006; Autry et al., 2011; Gronli et al., 2012; Nosyreva et al., 2013), 
suggesting that eEF2K-KO mice may exhibit altered responses to stressful events, which could be 
due to changes in the GABAergic transmission (Griebel and Holmes, 2013). 
We started our in vivo analysis by looking at proteomic changes in eEF2K-KO mice and focused 
our attention on three proteins that were regulated by eEF2K in vitro: eEF2, MAP1b, and Syn2b. 
We analyzed cortical P2 fractions and P2 fractions of brain slices containing the hippocampus that 
were used for electrophysiological analysis (see paragraph 3.2.2). In line with published data, 
quantitative WB analysis revealed a profound downregulation of peEF2 levels in eEF2K-KO mice 
relative to WT littermates, indicating that eEF2K activity is, indeed, abolished in the KO mice (Fig. 
17 A). Importantly, a small but significant upregulation of Syn2b levels was observed (Fig. 17 A, 
B). The analysis of eEF2 or MAP1b levels revealed no difference between eEF2K-KO mice and 
their WT littermates (data not shown). These results indicate that eEF2K activity negatively 
regulates Syn2b expression levels not only in vitro (see paragraph 3.1.2) but also in vivo. Instead, 
eEF2K activity does not appear to regulate expression levels of eEF2 or MAP1b in vivo, the former 
of which has also been observed by other groups working on eEF2K-KO mice (Park et al., 2008). 
This indicates that eEF2K activity may regulate some- but not all- proteins similarly in vitro and in 
vivo. 
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Figure 17: eEF2K-KO mice have increased Syn2b levels. A, WB analysis reveals abolished peEF2 and increased Syn2b levels in eEF2K-KO 
mice. P2 fractions of eEF2K-KO and WT littermates were prepared from cortex (left side of figure) and brain slices containing the hippocampus 
(right side of figure). P2 fractions were analyzed by WB for Syn2b and peEF2. B, Quantifications of band intensities of A. Band intensities are 
normalized by actin. Vertical axis shows the mean fold change vs. WT (WT set to a value of 1). Error bars are SEMs. At least five independent 
experiments were performed per condition. * p < 0.05 versus WT (student’s t-Test). 
 
3.2.2 eEF2K-KO mice have increased mIPSC frequency and potentiated 
mIPSCs 
 
Since we saw a strong effect of eEF2K activity in vitro on the functionality of both the pre- and 
postsynaptic compartment of the hippocampal/cortical GABAergic synapse (as opposed to an effect 
only on the presynaptic compartment of the glutamatergic synapse; see paragraph 3.1.5), we 
decided to focus our attention of the electrophysiological ex vivo experiments on the inhibitory 
synapse. More specifically, we decided to analyze mIPSCs of eEF2K-KO and WT mice littermates 
in granule cells of the (hippocampal) dentate gyrus which have well described electrophysiological 
properties related to GABAergic transmission (Mody et al., 1992; Staley et al., 1992; Glykys and 
Mody, 2007; Liang et al., 2008; Hortnagl et al., 2013). Worthy of note, mIPSC frequency is 
decreased in granule cells of Syn2-KO mice which was another reason for us to look at mIPSCs 
because we expected an increase of mIPSC frequency in eEF2K-KO mice as they exhibit increased 
Syn2b levels (see Fig. 17) (Medrihan et al., 2013). 
As expected, the analysis revealed a strong increase in mIPSC frequency in eEF2K-KO mice 
relative to WT littermates (Fig. 18 A, B). This result indicates that not only in vitro but also ex vivo 
eEF2K activity negatively controls vesicle release at the GABAergic synapse, even though- as 
mentioned before- changes in mIPSC frequency may also be related to changes in the amount of 
functional GABAergic synapses. As is the case in vitro, the change in mIPSC frequency may be 
mediated (at least in part) by changes in Syn2b expression levels ex vivo, as well (see paragraph 
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3.1.5 and 3.2.1), but we do not have a formal proof of this. The ex vivo results are also in line with 
the in vitro results because eEF2K-KO mice exhibit not only an increase in mIPSC frequency but 
also in amplitude (Fig. 18 A, B), suggesting that eEF2K activity either negatively regulates the 
efficacy and/or quantity of GABAARs but this result could also reflect a negative control of GABA 
in the GABAergic vesicles. Of note, the comparison of our electrophysiological results regarding 
mIPSC decay time in primary hippocampal neurons and in hippocampal granule cells in eEF2K-KO 
mice (Fig. 18, see also paragraph 3.1.5) also indicates that eEF2K activity may have differential 
effects on the kinetics of GABAARs in vitro and ex vivo. 
 
 
 
Figure 18: eEF2K-KO mice exhibit an increased mIPSC frequency and potentiated mIPSCs. A, Electrophysiological analysis of granule cells from 
(hippocampal) dentate gyrus reveals that slices from eEF2K-KO mice show an increase in mIPSC frequency and amplitude. Hippocampal slices of 
eEF2K-KO mice and WT littermates were prepared for electrophysiological analysis of mIPSCs in granule cells of the dentate gyrus. Representative 
traces of mIPSCs are shown for WT and eEF2K-KO animals. B, Quantification of A. Vertical axis shows Hz (for frequency), ms (for decay time), 
pA*ms (for area), and pA (for amplitude). Error bars are SEMs. Eleven neurons were analyzed per group. * p < 0.05 versus WT (student’s t-Test). 
 
3.2.3 eEF2K-KO mice present increased tonic inhibiton 
 
In order to have a more complete understanding of how eEF2K activity may affect the GABAergic 
system in vivo/ex vivo, we decided to analyze tonic inhibition. This is a form of neuronal inibition 
mediated by extrasynaptic GABAAR with high affinity for GABA, which are tonically activated by 
low concentrations of ambient/extrasynaptic GABA that presumably stems mainly from spillover of 
synaptically released GABA (Wei et al., 2003; Belelli et al., 2009; Egawa and Fukuda, 2013). Tonic 
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inhibition is clearly differentiable from the brief and intense phasic inhibition which is mediated by 
synaptically located GABAARs but, importantly, has a “strong integral inhibitory force” (Egawa 
and Fukuda, 2013) and therefore sets the “tone” of the GABAergic system (between 75-90% of 
total inhibition is due to tonic inhibition, depending on the cell type and brain region) (Nusser and 
Mody, 2002; Scimemi et al., 2005; Belelli et al., 2009; Errington et al., 2011; Richardson et al., 
2011). Again, we chose to do electrophysiological recordings of eEF2K-KO mice and WT 
littermates in granule cells of the (hippocampal) dentate gyrus where tonic inhibition is well-
described and accounts for around 75% of total inhibition (Nusser and Mody, 2002; Wei et al., 
2003; Scimemi et al., 2005; Glykys and Mody, 2007).  
The experimental framework we implemented to analyze tonic inhibition represents a slight 
modification of an existing design (Farisello et al., 2012) which registers both phasic and tonic 
currents and consists of three consecutive phases (Fig. 19 A): first, GABAergic currents under 
relatively physiological conditions are measured (KYN), then after stimulation with saturating 
amounts of exogenous GABA (GABA + KYN), and lastly after blocking GABAAR currents with a 
potent GABAAR antagonist (Bic + KYN). This gives an indication of tonic inhibition due to 
(endogenously) released GABA and associated spillover under “baseline”/physiological conditions 
(measured by the current shift Bic + KYN vs. KYN) and tonic inhibition which may present itself 
under conditions of elevated network activity (measured by the current shift GABA + KYN vs. 
KYN), such as during explorative behaviour or during seizures, where GABA concentrations can 
vary up to fivefold  (Minamoto et al., 1992; During and Spencer, 1993; Bianchi et al., 2003; 
Smolders et al., 2004; Scimemi et al., 2005; Bragina et al., 2008; Farisello et al., 2012). Of note, the 
current shift GABA + KYN vs. KYN is commonly interpreted as a change in the efficacy and/or 
amount of extracellular GABAARs since GABA is given in excess (Farisello et al., 2012). Lastly, 
one must keep in mind that tonic currents can be influenced by the activity of GABA transporters, 
which reduce amount of freely diffuseable GABA, and of course also depend on the amount of 
GABAergic synapses (Nusser and Mody, 2002; Scimemi et al., 2005; Qi et al., 2006; Bragina et al., 
2008). 
Interestingly, the analysis revealed that eEF2K-KO mice show a marked increase in tonic inhibition 
relative to WT littermates. More specifically, the current shift GABA + KYN vs. KYN was 
increased, however, the current shift Bic + KYN vs. KYN was not (Fig. 19 A, B). This indicates 
that ex vivo eEF2K activity negatively regulates tonic inhibition but only when network activity is 
strongly increased, such as during seizures (Scimemi et al., 2005). This may be due to less 
efficative and/or abundant extracellular GABAARs whose impact only becomes apparent if network 
activity (and associated GABA spillover) is elevated or it may be due to an increase in the activity 
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of GABA transporters under these conditions. Alternatively, eEF2K activity may also negatively 
control the number of GABAergic synapses which may cause detectable effects only under 
conditions of high network activity. And lastly, eEF2K activity may negatively regulate GABA 
release (see also paragraph 3.2.2) but this may only have a significant impact on tonic inhibiton 
when neurons become highly active. However, given that the current shift Bic + KYN vs. KYN is 
unaltered, the latter two explanations seem rather hypothetical (Farisello et al., 2012) and are (to the 
best of our knowledge) not backed up by a substantial amount of published data. Of note, the phasic 
currents (measurement of spontaneously occuring IPSCs) did not differ between eEF2K-KO and 
WT mice (data not shown), suggesting that eEF2K activity may actually have a stronger effect on 
tonic rather than on phasic inhibition ex vivo. This, in turn, could suggest that ex vivo eEF2K 
activity may negatively control the efficacy and/or quantity of extrasynaptic rather than synaptic 
GABAARs, though our previous data also suggests an effect on synaptically located GABAARs (see 
Fig. 18). Taken together with the results from paragraph 3.2.2., the data suggests that eEF2K 
activity regulates the functionality of the postsynaptic compartment of the GABAergic synapse not 
only in vitro but also ex vivo. More specifically, it appears to negatively regulate the efficacy and/or 
quantity of postsynaptic GABAARs. 
 
 
 
Figure 19: eEF2K-KO mice exhibit increased tonic inhibition. A, Electrophysiological analysis of granule cells from (hippocampal) dentate gyrus 
reveals that slices of eEF2K-KO mice exhibit an increased current shift from baseline when exogenous GABA is given in saturating concentrations 
but not under physiological conditions. Hippocampal slices of eEF2K-KO mice and WT littermates were prepared for electrophysiological analysis of 
GABAergic currents in granule cells of the dentate gyrus. GABAergic currents are measured during consecutive stages; first during KYN (3 mM), 
then during GABA (5 µM) + KYN (3 mM), and finally during Bic (20 µM) + KYN (3 mM). The dotted line represents the zero-current level. 
Representative traces are shown for WT and eEF2K-KO animals. B, Quantification of A. Vertical axis shows (tonic) GABAergic currents during 
GABA + KYN (as % of KYN). Error bars are SEMs. 16 neurons were analyzed per group. * p < 0.05 versus WT (student’s t-Test). C, Quantification 
of A. Vertical axis shows (tonic) GABAergic currents during Bic + KYN (as % of KYN). Error bars are SEMs. 10-13 neurons were analyzed per 
group.  
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3.2.4 eEF2K-KO mice exhibit a reduced susceptibility to chemoconvulsant 
agents 
 
Since we found that eEF2K-KO mice exhibit increased tonic inhibition and potentiated mIPSCs 
(see paragraph 3.2.2 and 3.2.3), we wanted to test if these mice show a decreased susceptibility to 
seizures relative to WT controls when they are challenged with convulsive substances. Indeed,  
there is an abundance of literature showing that the GABAergic system and associated phenomenon 
like tonic inhibition are causally related to seizures; e.g. many antiepileptic drugs activate the 
GABAergic response and a lower tonic inhibition appears to be one of the root causes of status 
epilepticus and seizures (Meldrum and Horton, 1980; Czuczwar, 1999; Mohler et al., 2002; 
Kobayashi and Buckmaster, 2003; Richerson, 2004; Klitgaard, 2005; Glykys and Mody, 2006; 
Farisello et al., 2012; Houser et al., 2012; Joshi and Kapur, 2012). Thus, we formulated the 
hypothesis that the absence of eEF2K activity should decrease the propensity for the development 
of seizures.   
We, therefore, chose to induce seizures by PTZ and pilocarpine in eEF2K-KO and WT mice while 
carrying out EEG recordings and analysis as previously described (Erbayat-Altay et al., 2008; Sala 
et al., 2010; Corradini et al., 2012). A sub-convulsive dose of PTZ (Jelenkovic et al., 2002) and a 
convulsive dose of pilocarpine (Vezzani, 2009) was used, which induced myoclonic or clonic & 
clonic-tonic seizure responses in WT mice, respectively (Fig. 21 A, B). As expected, eEF2K-KO 
mice exhibited a reduced response in both conditions, showing absence seizures for the PTZ 
treatment and a shift towards myoclonic seizures for the pilocarpine treatment. Additionally, 
classically analyzed EEG parameters clearly pointed towards a protection of eEF2K-KO mice from 
seizures (Fig. 21 A, B). These results strongly indicate that absence of eEF2K activity is associated 
with a decreased propensity for seizures. Notably, neither the relative weight of the EEG frequency 
bands nor the spontaneously occurring EEG spikes differed between eEF2K-KO and WT mice 
under baseline conditions (Fig. 20), indicating that while the absence of eEF2K activity decreases 
the susceptibility to seizures it does not have an effect on the activity level of the brain under 
baseline conditions (Whittingstall and Logothetis, 2009). In line with this, preliminary behavioural 
experiments testing for anxiety and other stress-related parameters (data not shown) did not reveal a 
difference between eEF2K-KO and WT mice which is in line with previous results published by 
another group (Ryazanov, 2002; Nosyreva et al., 2013). 
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Figure 20: eEF2K-KO mice exhibit normal baseline brain activity. EEG traces of two representative mice (WT and KO) and relative analysis 
reveals normal brain activity under baseline conditions in both genotypes. Quantifications of EEG parameters are also shown. Vertical axis shows 
relative δ, θ, α, and β EEG frequency bands (% of total spectral power) and No. of EEG spikes per 22 hours. Error bars are SEMs. N= 11 WT and N = 
7 KO. 
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Figure 21: eEF2K-KO mice are clearly less prone to seizures. A, B, EEG traces and analysis of eEF2K-KO mice reveals reduced responses to the 
convulsive substances PTZ (A) and pilocarpine (B). Quantifications of several behavioural and EEG parameters are also shown.Vertical axis shows 
latency to first epileptic seizure (racine stage 3-5), time spent in epileptiform activity, No. of EEG spikes per 100 min, and latency to death in animals 
showing tonic-clonic seizures. Error bars are SEMs. N= 7 for each group. * p < 0.05 and *** P< 0.001 versus WT (Student’s t-Test). 
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4 Discussion 
 
4.1 Summary of main findings 
 
The findings of our study mainly indicate two things (see Fig. 22): 1. chronic eEF2K activity 
downregulates the efficacy of the presynaptic compartment of both the excitatory and inhibitory 
synapse; 2. chronic eEF2K activity downregulates the efficacy of the inhibitory but not excitatory 
postsynaptic compartment. 
More specifically, eEF2K activity downregulates vesicle release by reducing Syn2b expression 
levels and it presumably does so by downregulating its translation rate since eEF2K activity leads to 
the phosphorylation and inactivation of eEF2, its only known substrate (Browne and Proud, 2002; 
Ryazanov, 2002). Additionally, at the GABAergic presynapse the amount of neurotransmitters in 
each vesicle may be reduced, as well, since eEF2K appears to downregulate GAD65 expression 
levels. To the best of our knowledge, we are the first group to show presynaptic effects induced by 
eEF2K, possibly since most research on this kinase in neuroscience has focused on acute, short-, 
and medium-term effects of eEF2K activity at the (excitatory) postsynaptic compartment, mainly in 
the context of NMDAR/mGluR activation and synaptic plasticity (Scheetz et al., 2000; Chotiner et 
al., 2003; Davidkova and Carroll, 2007; Piccoli et al., 2007; Sutton et al., 2007; Park et al., 2008; 
Verpelli et al., 2010; Autry et al., 2011). Additionally, eEF2K downregulates the efficacy/and or 
quantity of GABAARs, presumably by reducing the expression levels of yet unknown proteins. 
Perhaps, eEF2K activity changes expression levels of certain GABAAR subunits and could thereby 
affect the total amount or composition of GABAARs which may cause the aforementioned changes 
in GABAAR efficacy (Kilman et al., 2002; Liang et al., 2004; Eyre et al., 2012).  
Taken together, the findings of this study suggest that chronic eEF2K activity has a larger effect on 
the function of the GABAergic synapse/inhibitory system as opposed to the glutamatergic 
synapse/excitatory system. This, in turn, means that eEF2K may affect the excitation/inhibition 
balance which is relevant for applied research on and treatment of disorders of the nervous system 
and neurological disorders such as seizures/status epilepticus and epilepsy (Kilman et al., 2002; 
Fritschy, 2008; Yizhar et al., 2011). Indeed, our in vivo results point towards practical applications 
of manipulating eEF2K activity levels in the context of epilepsy since eEF2K-KO mice have a 
stronger GABAergic system and- expectedly- also exhibit a decreased susceptibility to seizures. 
Apparently, even though eEF2K-KO (and eEF2K-KI) mice have a normal degree of brain activity 
and exhibit normal behaviour under baseline conditions (Park et al., 2008; Gildish et al., 2012; 
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Nosyreva et al., 2013) (see also paragraph 3.2.4), they clearly exhibit increased GABAergic 
inhibition under conditions which mimic a state of elevated network activity (see paragraph 3.2.3). 
This, in turn, suggests that chronic absence of eEF2K activity may positively regulate a stress-
induced response of the organism aimed at regulating network activity. Therefore, one might be 
able to reduce seizure magnitude or susceptibility in patients by chronic administration of eEF2K 
inhibitors. Unfortunately, there are only few papers showing that commercially available eEF2K 
inhibitors like NH125 or rottlerin (Arora et al., 2003; Sutton et al., 2007; Autry et al., 2011) pass the 
blood–brain barrier (Autry et al., 2011) and several groups (including our own, data not shown) 
have found the inhibitors to be ineffective in reducing peEF2 levels both in vivo and in vitro (Chen 
et al., 2011; Devkota et al., 2012). It is important to point out that even though there are 
publications which show that the eEF2K/eEF2 pathway is involved in stress-responses (Ryazanov, 
2002; Dagestad et al., 2006; Autry et al., 2011; Gronli et al., 2012; Nosyreva et al., 2013), our study 
is the first which associates eEF2K activity with the GABAergic system and seizure susceptibility. 
 
 
 
Figure 22: eEF2K activity reduces the efficacy of the GABAergic synapse by regulating the expression levels of a subset of synaptic proteins. 
eEF2K phosphorylates and thereby inactivates eEF2, resulting in strongly reduced somatic and synaptic protein translation (Nairn et al., 1985; Mitsui 
et al., 1993; Ryazanov et al., 1997; Scheetz et al., 2000; Sutton et al., 2007) while the translation rate of a subset of synaptic proteins is increased 
(Scheetz et al., 2000; Chotiner et al., 2003; Davidkova and Carroll, 2007; Park et al., 2008; Autry et al., 2011). The process of eEF2 phosphorylation 
is indicated by the curved black arrow, whereas the up- and downregulation of mRNA translation is shown by the blue arrow and red T-bar, 
respectively (“AAAA” indicates polyadenylated mRNA which is accessible for protein translation). Our study shows that somatically or 
presynaptically localized eEF2K activity of the presynaptic neuron (left side of figure) leads to an upregulation of a subset of synaptic proteins such 
as MAP1b (not shown). It also leads to a downregulation of a subset of presynaptic and presynaptic vesicle-associated proteins, such as Syn2b and 
GAD 65. The downregulation of Syn2b leads to a reduction in vesicle release (reduction shown by red T-bar). Additionally, the downregulation of 
GAD65 levels probably leads to a reduction in the amount of GABA present in each vesicle (reduction shown by red T-bar) at the GABAergic 
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presynapse, which in turn could affect GABAAR efficacy (reduction shown by red T-bar). Somatically or postsynaptically localized eEF2K activity of 
the postsynaptic neuron (right side of figure) leads to an upregulation of a subset of synaptic proteins such as MAP1b or TRIM-3 (both not shown). It 
also leads to a downregulation of GABAAR efficacy at the inhibitory postsynapse (reduction shown by red T-bar), presumably by controlling 
expression levels of yet unknown proteins (e.g. a subset of GABAAR subunits). 
 
4.2 Data revision and outlook 
 
4.2.1 eEF2K gain-of-function experiments in vitro (primary rat/mouse 
neuronal cultures) 
 
In order to look at proteomic and functional changes induced by chronic eEF2K gain-of-function, 
we chose primary neuronal cultures as our experimental model since they are easily accessible to 
experimental manipulations- e.g. lentiviral infection to increase the amount of eEF2K expressed in 
neurons (Boulton et al., 1992; Ding and Kilpatrick, 2013). It is important to note that eEF2K gain-
of-function (via lentiviral infection of eEF2Kca) was introduced in immature neurons (DIV 1) and 
the analysis was carried out on mature neurons (DIV 20). This means that the data of this in vitro 
approach may not only reflect what kind of effect eEF2K has on mature networks but may also 
reflect changes in mature networks that actually stem from eEF2K-dependent developmental 
processes. Indeed, carrying out the infection with eEF2Kca at DIV 10 (where neurons are already 
much more mature than at DIV 1 but are not considered fully matured yet) (Murata and 
Constantine-Paton, 2013) had an effect on the expression rate of one of the proteins that were 
identified to be regulated by eEF2K when infection took place at DIV 1 (see Fig. 9), indicating that 
developmental processes may, in part, be reflected by the analysis. 
To analyze eEF2K-dependent proteomic changes that occur after chronic overexpression/gain-of-
function of eEF2K, we implemented a highly quantitative SILAC-based mass spectrometry 
approach  (Ibarrola et al., 2003; Ong and Mann, 2006; Liao et al., 2008). With this approach we 
identified “eEF2K-regulated” proteins by comparing the relative quantity of identified 
peptides/proteins in the P2 fraction of eEF2Kca with the relative quantity in the P2 fraction of the 
GFP control (see paragraph 3.1.1). “Upregulated” proteins are proteins which exhibit an eEF2Kca 
to GFP ratio which is greater than one, whereas “downregulated” proteins exhibit an eEF2Kca to 
GFP ratio which is smaller than one. Since the P2 fraction is enriched in synaptic components (Li et 
al., 1996; Ohno et al., 2004) (see also Fig. 5), proteomic changes in this fraction are indicative of 
changes in protein levels at the synapse (both of the pre- and postsynaptic compartment) and are 
probably due to eEF2K-dependent regulation at the translational level involving the 
phosphorylation/inactivation of eEF2, the only known substrate of eEF2K (Mitsui et al., 1993; 
Browne and Proud, 2002). As a consequence of eEF2 inactivation, global translation is reduced but 
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the local translation at the synapse of a small subset of synaptic proteins is actually increased by yet 
not well-understood mechanisms (Marin et al., 1997; Scheetz et al., 2000; Park et al., 2008). This 
eEF2K-dependent local translation has been described at the postsynapse (of the excitatory synapse) 
but it is conceivable that this form of local translation may also take place in the presynaptic 
compartment (Yoon et al., ; Lin and Holt, 2007; Akins et al., 2009). Therefore, the proteomic 
changes we see in the P2 fraction could be the result of eEF2K-dependent translation control at the 
soma or at the synapse (i.e. local) but based on our experimental setup we cannot distinguish 
between the two. It is also important to keep in mind the technical limitations of the SILAC-based 
mass spectrometry readout: any mass spectrometry analysis is biased towards proteins which are 
relatively abundant and/or easily detectable (e.g. proteins which are easily ionizeable) (Wysocki et 
al., 2005). Additionally, metabolic labeling methods like SILAC are intrinsically biased towards 
proteins with high turnover rates and depend on cell growth which poses a technical challenge for 
implementing SILAC in neurons as opposed to mitotically deviding cells (Ong and Mann, 2006; 
Wu et al., 2012). Nonetheless, since synaptic proteins have a half-lifetime between two to five days 
(Cohen et al., 2013) and our isotope integration took place for 20 days we can be quite sure that the 
SILAC procedure was successfully implemented to assess proteomic changes, especially since we 
were able to demonstrate an average isotope incorporation rate of 95% in our experimental design 
(Fig. 4).  
In our SILAC-based screen we identified three synaptic proteins whose expression levels are 
upregulated by chronic eEF2K gain-of-function: MAP1b, eEF2, and TRIM3 (Fig. 6). All of these 
proteins have been described to be localized to the synapse and have well-described synaptic 
functions (Davidkova and Carroll, 2007; Park et al., 2008; Hung et al., 2010), though it is 
noteworthy that they are not exclusively localized to the synapse (Verpelli et al., 2010; Bhanot et 
al., 2011; Labonte et al., 2013). Interestingly, Davidkova and Carroll demonstrated that acute 
mGluR-induced upregulation of MAP1b depends on eEF2K activity (Davidkova and Carroll, 2007) 
which indicates that eEF2K may upregulate MAP1b levels both chronically and in response to 
acute stimuli. In contrast, upregulation of eEF2 and TRIM3 has (to the best of our knowledge) not 
been related to eEF2K activity. Due to the fact that eEF2K vastly downregulates global translation 
(Ryazanov et al., 1988; Scheetz et al., 2000; Browne and Proud, 2002; Dorovkov et al., 2002), 
“upregulated” proteins as identified in our screen may also represent proteins whose translation rate 
is downregulated less strongly than that of the majority of proteins. One way to analyze whether 
eEF2K indeed increases the translation rate of the proteins at hand is to carry out protocols aimed at 
activating eEF2K- e.g. via NMDAR activation (Scheetz et al., 2000) or by the use of eEF2K 
activators (Chen et al., 2011; Devkota et al., 2012)- and then register whether the expression levels 
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of the identified proteins increase accordingly. Instead, the synaptic proteins whose expression 
levels are downregulated by chronic eEF2K gain-of-function comprise several presynaptic proteins, 
many of which are vesicle-associated like Syn2b (Tab. 2, Fig. 6) (Medrihan et al., 2013). This 
suggests that eEF2K activity downregulates the expression level of presynaptic vs. postsynaptic 
proteins, a concept that we then validated in the course of the study with an immunocytochemical 
approach (see paragraph 3.1.3). To the best of our knowledge there is no publication showing 
eEF2K-dependent proteomic changes at the presynapse but rather at the postsynapse, which may be 
due to the fact that most eEF2K-related research at the synapse has focused on GluR-mediated 
changes in eEF2K activity (Scheetz et al., 1997, 2000; Verpelli et al., 2010; Autry et al., 2011). 
We then focused on MAP1B and eEF2 as representatives of eEF2K-regulated proteins and showed 
that their regulation does not depend on changes at the transcriptional level and does not depend on 
an increase in eEF2K molecules per se but, as expected, depends on an increase in eEF2K activity 
(for this we used K170M, a catalytically inactive form of eEF2; see paragraph 3.1.2). This indicates 
that proteomic changes induced by eEF2K are probably due to its control of translation via eEF2-
phosphorylation (Browne and Proud, 2002). However, we cannot exclude the possibility that 
eEF2K activity leads to proteomic changes by affecting the stabilization/degradation of the 
regulated proteins (Vogel and Marcotte, 2012). To clarify whether changes in protein levels are 
really due to changes at the translational level one could compare the polysome profiles of eEF2K-
regulated mRNAs (like that of MAP1b ) between GFP and eEF2Kca (Schratt et al., 2004; Roffe et 
al., 2010; Moreno et al., 2012). E.g. in the case of upregulated proteins one would expect a shift of 
the profile towards the polyribosomal fraction in eEF2Kca relative to GFP which would indicate 
that the active translation of the mRNAs is higher in eEF2Kca than in the GFP control. Another 
important question is whether eEF2K activity directly or indirectly affects the expression level of 
eEF2K-regulated proteins. E.g. eEF2K activity may affect the expression level of a certain protein 
which is involved in protein synthesis (like e.g. eEF2, see Tab. 1 or 2) which, in turn, might lead to 
subsequent changes in the proteome. One (laborious) way of addressing this point would be to 
chronically manipulate the expression level of each regulated protein (e.g. eEF2) independently of 
eEF2K in a way which mimics the change induced by chronic eEF2K overexpression (here: one 
would have to increase eEF2 expression levels). If subsequent proteomic changes resemble those of 
overexpressing eEF2K (e.g. upregulation of MAP1b), eEF2K activity probably does not directly 
affect the expression level of the eEF2K-regulated proteins but rather does so indirectly via the 
regulation of a mediating protein (here: eEF2). 
To analyze eEF2K-dependent functional changes at the synapse that occur after chronic 
overexpression/gain-of-function of eEF2K, we compared GFP, eEF2Kca, and K170M at DIV 20 
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with immunocytochemical and electrophysiological approaches (see paragraph 3.1.3, 3.1.4., and 
3.1.5). In line with our previous finding that eEF2K downregulates the expression rate of 
presynaptic vesicle-associated proteins which are known to change SV dynamics like Syn2b, we 
found that eEF2K activity downregulates vesicle release. Importantly, using Syn TKO cultures and 
a Syn2b rescue design (3.1.5) we were able to show that the eEF2K-induced downregulation of 
Syn2b leads to a reduction of vesicle release, pointing towards the central role of Syn2b in 
mediating the eEF2K-induced effects at the presynapse. Taken together, these results suggest that 
eEF2K downregulates the efficacy of the presynaptic compartment/ vesicle release by reducing the 
expression levels of a subset of presynaptic vesicle-associated proteins such as Syn2b. However, 
one must be cautious about explaining the strong effect that eEF2K activity has on vesicle release 
solely by the regulation of Syn2b since the downregulation is only around 25 % (Tab. 2) but in the 
context of the rescue experiment the Syn2b levels were increased well above GFP baseline levels in 
eEF2Kca by co-overexpression of Syn2b (Fig. 16). This consideration is especially relevant since 
there are indications that Syn2b overexpression can result in increased vesicle release (Gitler et al., 
2008) which could mean that the Syn2b overexpression might outdo any effect that eEF2K 
overexpression may have on vesicle release. Also, since eEF2K downregulates global translation 
one has to ask the question how eEF2K achieves protein specific downregulation of protein 
expression rates, like for Syn2b- our study does not give an answer to this question but we believe it 
merits further research. Nonetheless, our results are in line with published data which shows that 
there are proteins whose expression rates are particularly repressed by eEF2K activity- one example 
is BDNF at the excitatory postsynapse (Autry et al., 2011). 
Importantly, the electrophysiological analysis also revealed another interesting effect that chronic 
eEF2K gain-of-function has on the synapse: apparently eEF2K activity leads to a downregulation of 
the efficacy of the postsynaptic compartment of the inhibitory synapse but does not affect the 
efficacy of the excitatory postsynapse. More specifically, in rat primary cortical cultures eEF2K 
appears to downregulate the mIPSC area, decay time, and amplitude whereas the corresponding 
mEPSC parameters are not changed (3.1.5). This means that chronic eEF2K activity probably 
downregulates GABAAR quantity, kinetics, and/or efficacy (i.e. the ability of GABAARs to exert an 
inhibitory effect on the postsynaptic neuron in response to activation via the endogenous ligand, 
GABA). Worthy of note, we can show that this postsynaptic effect that eEF2K has on the inhibitory 
synapse takes place independently of Syn regulation and therefore dissociates Syn2b 
downregulation from the downregulation of GABAAR efficacy. Instead, the effect could very well 
be due to other proteomic regulations that occur during eEF2K gain-of-function, such as MAP1b 
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upregulation, especially since MAP1b has been associated with GABAR anchoring at the inhibitory 
postsynapse (Allison et al., 2000). 
 
4.2.2 eEF2K loss-of-function in vivo and ex vivo (eEF2K-KO mice and slices 
thereof) 
 
We also wondered if our in vitro results could be replicated in vivo and what kind of effects a 
chronic change of eEF2K activity may have on a highly orchestrated neural network such as the 
brain of a mammal which obviously has a much higher level of complexity and cellular 
organization than a primary neuronal culture (Boulton et al., 1992). Our main motivation for this 
was to see whether changing eEF2K activity may have practical applications for patients suffering 
from neurological disorders such as epilepsy, since our in vitro results indicated an eEF2K-
dependent effect on the excitation/inhibition balance (Kilman et al., 2002; Fritschy, 2008; Yizhar et 
al., 2011) (see also paragraph 3.1.5). For this, we analyzed eEF2K-KO mice which represent a 
genetic model to analyze the effects of chronic absence of physiological eEF2K activity. In this 
model we expected opposite effects of the (chronic) gain-of-function experiments in vitro. This 
assumption seems justified as gene-dosage effects have been previously described for eEF2K in 
neurons, both in vivo/ex vivo and in vitro (Park et al., 2008; Im et al., 2009; Verpelli et al., 2010; 
Gildish et al., 2012). However, it is important to keep in mind the limitations of such genetic 
models since genetic deletion in vivo has been shown to cause compensatory effects that mask 
obvious phenotypes which would otherwise be observed, thereby limitating the power of these 
approaches to reveal effects associated with gene deletion (Thyagarajan et al., 2003; van 
Amerongen and Berns, 2006; Barbaric et al., 2007). In line with this fact, eEF2K-KO mice have no 
obvious phenotypes (normal weight and behaviour, normal baseline brain activity levels and 
excitatory transmission) (Ryazanov, 2002; Park et al., 2008; Nosyreva et al., 2013) (see also 
paragraph 3.2.4). Nonetheless, there are published phenotypes of eEF2K-KO mice (Park et al., 
2008; Autry et al., 2011; Nosyreva et al., 2013) and associations of the eEF2K/eEF2 pathway with 
stress (Ryazanov, 2002; Dagestad et al., 2006; Gronli et al., 2012) which may be related to changes 
in the excitation/inhibition balance caused by eEF2K activity (Griebel and Holmes, 2013).  
Our WB analysis revealed that eEF2K-KO mice have a small increase in Syn2b expression levels 
but the levels of MAP1b and eEF2 do not appear to be altered (see paragraph 3.2.1). This means 
that not all but some proteomic changes are specular in our in vitro and in vivo design. Interestingly, 
a subsequent electrophysiological (see paragraph 3.2.2) analysis revealed that eEF2K-KO mice 
exhibit an increase in mIPSC frequency which may be due to the increase of Syn2b levels though 
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we have no formal proof of this. This suggests that eEF2K activity negatively regulates vesicle 
release at the GABAergic synapse not only in vitro but also in vivo. This concept is absolutely 
novel and has (to the best of our knowledge) not been described in literature. As expected from our 
in vitro results, there was also an increase of mIPSC amplitude and a strong trend for an increase in 
mIPSC area in the KO mice indicating that eEF2K activity negatively regulates the efficacy of the 
GABAergic postsynapse/GABAARs both in vitro and in vivo. Interestingly, eEF2K-KO mice also 
presented a stronger tonic inhibition under conditions which may present themselves under elevated 
network (see paragraph 3.2.3). Taken together, these results indicate that in vivo physiological 
eEF2K activity negatively regulates the efficacy of the GABAergic system and this effect may 
become particularly pronounced when there is an increase of network activity, e.g. in the context of 
stressful events like kindling or seizures. Accordingly, eEF2K-KO mice responded much less to 
seizure induction by chemoconvulsant substances than WT mice (see paragraph 3.2.4) which may 
be due to their larger GABAergic response that presents itself in the context of stressful events. The 
results of this in vivo study therefore indicate that eEF2K may be a good target for chronically 
administered antiepileptic drugs aimed at inhibiting eEF2K since chronic loss of eEF2K activity 
does not change the baseline brain activity level of an organism nor does it change its behaviour. 
But importantly, chronic loss of eEF2K activity does appear to reduce the susceptibility of the 
organism to develop seizures. 
These interesting in vivo results raise a lot of questions which could be addressed in future studies. 
For example, is eEF2K really a good target for antiepileptic drugs? This would have to be addressed 
by the use of an efficient and specific eEF2K inhibitor that passes the blood–brain barrier. As 
mentioned in 4.1 the available inhibitors do not appear to fulfill these criteria. If our hypothesis is 
correct, chronic use of an adequate eEF2K inhibitor should not affect the patient under normal 
conditions, i.e. it should not change the well-being of the patient when the activity level of his brain 
is within the physiological range. Instead, if the patient experiences a strong increase in network 
activity (such as during seizures), eEF2K should exhibit a moderating effect on neuronal activation. 
However, we cannot guarantee that downregulation of eEF2K activity (as in the case of chronically 
administered eEF2K inhibitors) would show similar effects as an absence of eEF2K activity (as in 
eEF2K-KO mice). E.g. it could be that eEF2K-KO mice compensate eEF2K deficits under 
physiological conditions by changing the expression of other proteins but do not compensate the 
deficits when the neuronal network is being “challenged”, such as during elevated network activity 
(Barbaric et al., 2007; Bragina et al., 2008; Nosyreva et al., 2013). This could lead to the faulty 
hypothesis that chronic reduction of eEF2K activity should only show effects under elevated 
network activity. Additionally, one must keep in mind that eEF2K is a ubiquitous protein and 
   4 Discussion 
 
 
   64 
therefore changes in eEF2K activity may affect not only the brain but all organs of the body or may 
result in changes in the responses of the organism to pathophysiological conditions like cancer 
(Nairn et al., 1985; Ahmed et al., 2005; Leprivier et al., 2013).  
Another interesting question to address in further studies is to better understand by which means 
eEF2K activity affects the excitation/inhibition imbalance and how this may relate to the fact that 
eEF2K-KO mice have a reduced susceptibility for seizures. For example, it would be interesting to 
decipher if changes in eEF2K activity in vivo really change the translation rate of specific proteins 
and whether these changes are the cause of the stronger GABAergic system that we witnessed in 
eEF2K-KO mice. Lastly, a fascinating question is whether eEF2K and the eEF2K/eEF2 pathway 
have an essential biological function at the synapse- what kind of an evolutionary advantage might 
the employment of this translation control machinery have in the context of synapse- and network-
functionality? One idea proposed by researchers is that the eEF2K/eEF2 pathway acts as a decoding 
device for neuronal activity at the synapse, which dynamically changes the synaptic proteome in 
response to changes in network activity, possibly in order to enable specific changes in protein 
expression that are demanded by different states of network activity (Davidkova and Carroll, 2007; 
Sutton et al., 2007; Park et al., 2008; Autry et al., 2011; Nosyreva et al., 2013). Since our study 
indicates that eEF2K activity and the extent of seizures are related, it would be interesting to see if 
the eEF2K/eEF2 pathway is utilized by organisms to control network activity and associated events 
like seizures. This would mean that the eEF2K/eEF2 pathway does not only act as decoding device 
for network activity but may, itself, control the extent of network activity.  
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5 Abbreviations 
 
 
Common abbreviations are not shown.  Of note, the International System of Units was applied throughout this study. 
 
 
a    = adeonsine 
aa    = amino acids 
AMPK    = AMP-activated protein kinase 
AMPAR   = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
ANOVA   = analysis of variance 
Arc    = activity-regulated cytoskeletal-associated protein 
Arg    = Arginine 
ATP    = adenosine triphosphate 
BDNF    = Brain-derived neurotrophic factor 
Bic    = Bicuculline 
c    = cytosine 
CaM    = calmodulin 
CaMKII   = Ca
2+
/Calmodulin-dependent kinase II 
CaMKIII   = Ca
2+
/Calmodulin-dependent kinase III 
C-terminal   = carboxyl-terminus 
Cy    = cyanine/ cyanine dye 
DAPI    = 4',6-diamidino-2-phenylindole 
dd     = double distilled 
DIV    = days in vitro 
DNA    = deoxyribonucleic acid 
DTT    = dithiothreitol 
E    = embryonic day 
e.g.    = for example 
eEF2    = eukaryotic elongation factor 2  
eEF2K    = eukaryotic elongation factor 2 kinase 
eEF2Kca   = constituitively active eukaryotic elongation factor 2 kinase  
eEF2K-KO   = eukaryotic elongation factor 2 kinase-knockout 
eEF2K-KI   = eukaryotic elongation factor 2 kinase-knockin 
EEG    = electroencephalography 
EPSC    = excitatory postsynaptic current 
FDR    = false discovery rate 
Fig.    = Figure 
FITC    = Fluorescein isothiocyanate 
g    = guanine 
GABA    = gamma-Aminobutyric acid 
GABAAR   = GABAA receptor 
GABAARα1   = α1 subunit of the GABAA receptor 
GABAR   = GABA receptor 
GAPDH   = glyceraldehyde 3-phosphate dehydrogenase 
GFP    = Green fluorescent protein 
GluR    = glutamate receptor 
GluR1/GRIA1   = subunit 1 of the AMPAR 
 
   5 Abbreviations 
 
 
   66 
GTP    = guanosine triphosphate 
i.e.    = that means 
i.p.    = intraperitoneal injection 
IF     = immunofluorescence 
IgG    = Immunoglobulin G 
IPSC    = inhibitory postsynaptic current 
K170M   = catalytically inactive eukaryotic elongation factor 2 kinase 
kDa    = kilodalton 
KYN    = Kynurenic acid 
LC-MS/HPLC-MS  = Liquid chromatography–mass spectrometry 
Lys    = Lysine 
MAP1b   = Microtubule-associated protein 1B 
MAP2    = Microtubule-associated protein 2 
MEK/ERK   = mitogen-activated protein/extracellular signal-regulated kinase 
mEPSC   = miniature excitatory postsynaptic current 
Met    = Methionine 
mGluR-LTD   = mGluR-dependent-Long Term Depression 
mIPSC    = miniature inhibitory postsynaptic current 
mPSC    = miniature postsynaptic current 
mRNA    = messenger ribonucleic acid 
MS    = mass spectrometry 
mTOR    = mammalian target of rapamycin 
N     = number of raw values per experimental group  
n.d.    = no publishing date 
n.p.    = no publisher name 
NMDAR    = N-methyl-D-aspartate receptor 
NLGN1   = neuroligin-1 
No.    = number 
N-terminal   = amino-terminus 
P    = postnatal day 
P1    = nuclear fraction 
P2    = (crude) synaptosomal fraction 
PCR    = polymerase chain reaction 
p70S6K   = P70S6 kinase  
p90RSK1   = p90 ribosomal S6 kinase 
PSD95    = Postsynaptic Density protein 95 
PSC    = postsynaptic current 
PTZ    = pentylenetatrazol 
RNA    = ribonucleic acid 
RT-PCR   = Real-time polymerase chain reaction 
Ser    = Serine 
SAP    = Synapse-associated protein 
SD    = standard deviation; σ 
SDS    = sodium dodecyl sulfate 
SDS-PAGE   = sodium dodecyl sulfate-Polyacrylamide gel electrophoresis 
SEM    = standard error of mean 
sieEF2K   = small interference ribonucleic acid 362 
SILAC    = stable isotope labeling in cell culture 
siRNA    = small interference ribonucleic acid 
sreEF2K   = small interference ribonucleic acid 362-resistant form of  
   5 Abbreviations 
 
 
   67 
eukaryotic elongation factor 2 kinase  
SV     = synaptic vesicles 
Syp    = Synaptophysin 
Syn    = Synapsin 
SYT    = Synaptotagmin 
t    = thymine 
Tab.    = table 
Thr    = Threonin 
TL    = total lysate 
TKO    = Synapsin 1-3 knockout 
TBS    = Tris-buffered saline 
TBS-T    = Tris-buffered saline-Tween 
tRNA    = Transfer ribonucleic acid 
TTX    = tetrodotoxin 
v    = volume 
VGAT    = vesicular gamma-Aminobutyric acid transporter 
VGLUT   = vesicular glutamate transporter 
w    = weight 
WB    = Western Blot 
WT    = wild type 
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